WO1997007233A9 - Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors - Google Patents
Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptorsInfo
- Publication number
- WO1997007233A9 WO1997007233A9 PCT/US1996/013077 US9613077W WO9707233A9 WO 1997007233 A9 WO1997007233 A9 WO 1997007233A9 US 9613077 W US9613077 W US 9613077W WO 9707233 A9 WO9707233 A9 WO 9707233A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- cell
- receptors
- signalling
- signal transduction
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title claims abstract description 123
- 230000003915 cell function Effects 0.000 title claims abstract description 35
- 230000005014 ectopic expression Effects 0.000 title description 6
- 230000033228 biological regulation Effects 0.000 title description 4
- 230000037361 pathway Effects 0.000 claims abstract description 128
- 230000019491 signal transduction Effects 0.000 claims abstract description 82
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 60
- 230000001131 transforming Effects 0.000 claims abstract description 43
- 230000003213 activating Effects 0.000 claims abstract description 27
- 230000001105 regulatory Effects 0.000 claims abstract description 19
- 230000004913 activation Effects 0.000 claims abstract description 18
- 210000004027 cells Anatomy 0.000 claims description 364
- 102000005962 receptors Human genes 0.000 claims description 248
- 108020003175 receptors Proteins 0.000 claims description 248
- 210000003494 Hepatocytes Anatomy 0.000 claims description 50
- 102000004852 Thyrotropin-releasing hormone receptors Human genes 0.000 claims description 42
- 108090001094 Thyrotropin-releasing hormone receptors Proteins 0.000 claims description 41
- 210000004185 Liver Anatomy 0.000 claims description 38
- 230000001404 mediated Effects 0.000 claims description 32
- 230000003612 virological Effects 0.000 claims description 32
- 230000003834 intracellular Effects 0.000 claims description 27
- 102000034378 G proteins Human genes 0.000 claims description 26
- 108091006011 G proteins Proteins 0.000 claims description 26
- 241000701161 unidentified adenovirus Species 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 14
- 102000011923 Thyrotropin Human genes 0.000 claims description 13
- 108010061174 Thyrotropin Proteins 0.000 claims description 13
- 229940079593 drugs Drugs 0.000 claims description 13
- 102000004310 Ion Channels Human genes 0.000 claims description 12
- 108090000862 Ion Channels Proteins 0.000 claims description 12
- 230000004116 glycogenolysis Effects 0.000 claims description 12
- 102000019460 EC 4.6.1.1 Human genes 0.000 claims description 11
- 108060000200 EC 4.6.1.1 Proteins 0.000 claims description 11
- 102000014469 EC 4.6.1.2 Human genes 0.000 claims description 10
- 108010078321 EC 4.6.1.2 Proteins 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 10
- 108091007915 enzyme-linked receptors Proteins 0.000 claims description 10
- 102000027638 enzyme-linked receptors Human genes 0.000 claims description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000000056 organs Anatomy 0.000 claims description 10
- 102000027637 ion channel-linked receptors Human genes 0.000 claims description 9
- 108091007916 ion channel-linked receptors Proteins 0.000 claims description 9
- 102000005969 steroid hormone receptors Human genes 0.000 claims description 8
- 108020003113 steroid hormone receptors Proteins 0.000 claims description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 102000027730 retinoid hormone receptors Human genes 0.000 claims description 7
- 108091008001 retinoid hormone receptors Proteins 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 230000002194 synthesizing Effects 0.000 claims description 7
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 7
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- 239000004382 Amylase Substances 0.000 claims description 5
- 102000013142 Amylases Human genes 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 238000004220 aggregation Methods 0.000 claims description 5
- 235000019418 amylase Nutrition 0.000 claims description 5
- 229960001340 histamine Drugs 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 108091007921 receptor tyrosine kinases Proteins 0.000 claims description 5
- 102000027656 receptor tyrosine kinases Human genes 0.000 claims description 5
- 239000005495 thyroid hormone Substances 0.000 claims description 5
- 208000006386 Bone Resorption Diseases 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 4
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 4
- 101700064507 MARK2 Proteins 0.000 claims description 4
- 102100000541 MARK2 Human genes 0.000 claims description 4
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 4
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 4
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 claims description 4
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 claims description 4
- 102100000775 REN Human genes 0.000 claims description 4
- 108090000783 Renin Proteins 0.000 claims description 4
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims description 4
- 229960001727 Tretinoin Drugs 0.000 claims description 4
- 102000004305 alpha adrenergic receptors Human genes 0.000 claims description 4
- 108090000861 alpha adrenergic receptors Proteins 0.000 claims description 4
- 102000001307 androgen receptors Human genes 0.000 claims description 4
- 108010080146 androgen receptors Proteins 0.000 claims description 4
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 4
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 4
- 230000024279 bone resorption Effects 0.000 claims description 4
- 230000003291 dopaminomimetic Effects 0.000 claims description 4
- 102000015694 estrogen receptors Human genes 0.000 claims description 4
- 108010038795 estrogen receptors Proteins 0.000 claims description 4
- 230000004110 gluconeogenesis Effects 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 230000004130 lipolysis Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000002263 peptidergic Effects 0.000 claims description 4
- 102000003998 progesterone receptors Human genes 0.000 claims description 4
- 108090000468 progesterone receptors Proteins 0.000 claims description 4
- 230000006259 progesterone secretion Effects 0.000 claims description 4
- 108091007923 receptor tyrosine phosphatases Proteins 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 230000000862 serotonergic Effects 0.000 claims description 4
- 102000027575 transmembrane receptors Human genes 0.000 claims description 4
- 108091007901 transmembrane receptors Proteins 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 108091007918 tyrosine-kinase associated receptors Proteins 0.000 claims description 4
- 102000027654 tyrosine-kinase associated receptors Human genes 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000586 desensitisation Methods 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 102000003922 Calcium Channels Human genes 0.000 claims 3
- 108090000312 Calcium Channels Proteins 0.000 claims 3
- 102000011045 Chloride Channels Human genes 0.000 claims 3
- 108010062745 Chloride Channels Proteins 0.000 claims 3
- 102000018674 Sodium Channels Human genes 0.000 claims 3
- 108010052164 Sodium Channels Proteins 0.000 claims 3
- 230000004118 muscle contraction Effects 0.000 claims 3
- 102000004257 potassium channel family Human genes 0.000 claims 3
- 108020001213 potassium channel family Proteins 0.000 claims 3
- 230000026731 protein phosphorylation Effects 0.000 claims 3
- 102000009310 vitamin D receptors Human genes 0.000 claims 3
- 108050000156 vitamin D receptors Proteins 0.000 claims 3
- 101700083699 HIS6 Proteins 0.000 claims 2
- 101710008935 hisHF Proteins 0.000 claims 2
- 102000017178 Guanylate Cyclase-Coupled Receptors Human genes 0.000 claims 1
- 108010013990 Guanylate Cyclase-Coupled Receptors Proteins 0.000 claims 1
- 230000027455 binding Effects 0.000 description 47
- PBGMJEFISXYLCY-AVGNSLFASA-N (2S)-N-[(2S)-1-[(2S)-2-amino-3-(1-methylimidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]-5-oxopyrrolidine-2-carboxamide Chemical compound CN1C=NC(C[C@H](N)C(=O)N2[C@@H](CCC2)C(=O)NC(=O)[C@H]2NC(=O)CC2)=C1 PBGMJEFISXYLCY-AVGNSLFASA-N 0.000 description 43
- XNSAINXGIQZQOO-SDDRHHMPSA-N (2S)-N-[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)[C@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SDDRHHMPSA-N 0.000 description 38
- 241000700605 Viruses Species 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 34
- 108060008623 TRH Proteins 0.000 description 34
- 102100009392 TRH Human genes 0.000 description 34
- 229940034199 Thyrotropin-Releasing Hormone Drugs 0.000 description 34
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 239000003446 ligand Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 229920002676 Complementary DNA Polymers 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 210000004369 Blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 229940095074 Cyclic AMP Drugs 0.000 description 18
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- GUBXYMKIJFOYOA-YMGPVYFXSA-N [(2R)-2-formyloxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] formate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(=O)OC[C@@H](COC=O)OC=O)[C@H](O)[C@@H]1O GUBXYMKIJFOYOA-YMGPVYFXSA-N 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 14
- 210000001519 tissues Anatomy 0.000 description 13
- 229940088597 Hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- -1 retinoids Substances 0.000 description 12
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 11
- 229960000367 Inositol Drugs 0.000 description 11
- 210000002966 Serum Anatomy 0.000 description 11
- 230000035492 administration Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 108020004999 Messenger RNA Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229920002106 messenger RNA Polymers 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940096919 Glycogen Drugs 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 8
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 230000000051 modifying Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 229960003726 vasopressin Drugs 0.000 description 8
- 210000000170 Cell Membrane Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 7
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 7
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 101710025911 ACTG1 Proteins 0.000 description 6
- 102100017353 ACTG1 Human genes 0.000 description 6
- 102000001253 Protein Kinases Human genes 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 210000000805 Cytoplasm Anatomy 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 229960004666 Glucagon Drugs 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- INAPMGSXUVUWAF-XCMZKKERSA-N 1D-myo-inositol 6-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-XCMZKKERSA-N 0.000 description 4
- 102000003852 Autoantibodies Human genes 0.000 description 4
- 108090000206 Autoantibodies Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101710007887 DHFR Proteins 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000003240 Portal Vein Anatomy 0.000 description 4
- 108060006633 Protein Kinases Proteins 0.000 description 4
- 108020004440 Thymidine Kinase Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 208000007089 Vaccinia Diseases 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 102000016350 Viral Proteins Human genes 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 239000000048 adrenergic agonist Substances 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 229960004373 Acetylcholine Drugs 0.000 description 3
- 102000009914 Adenosine deaminases Human genes 0.000 description 3
- 108091022188 Adenosine deaminases Proteins 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N Cyclic guanosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108010027570 EC 2.4.2.22 Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 description 3
- 229940040129 Luteinizing Hormone Drugs 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 108060006375 POMC Proteins 0.000 description 3
- 102100008873 POMC Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000003911 Thyrotropin receptors Human genes 0.000 description 3
- 108090000253 Thyrotropin receptors Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 102000034433 acetylcholine receptors Human genes 0.000 description 3
- 108020000715 acetylcholine receptors Proteins 0.000 description 3
- 102000006646 aminoglycoside phosphotransferase family Human genes 0.000 description 3
- 230000003182 bronchodilatating Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 101710024922 hyg Proteins 0.000 description 3
- 230000002458 infectious Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001817 pituitary Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002685 pulmonary Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001177 retroviral Effects 0.000 description 3
- 230000003248 secreting Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 208000006673 Asthma Diseases 0.000 description 2
- 101710002767 BACOVA_02645 Proteins 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 101710010587 CASP13 Proteins 0.000 description 2
- 210000003996 CFU-GM Anatomy 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 101700014779 GLB1 Proteins 0.000 description 2
- 102100014497 GOLPH3 Human genes 0.000 description 2
- 101710008339 GOLPH3 Proteins 0.000 description 2
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 229940097277 Hygromycin B Drugs 0.000 description 2
- 206010020993 Hypoglycaemia Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 206010022498 Insulinoma Diseases 0.000 description 2
- 210000004731 Jugular Veins Anatomy 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 210000004165 Myocardium Anatomy 0.000 description 2
- 101700062818 NP Proteins 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 101710043203 P23p89 Proteins 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940053200 antiepileptics Fatty acid derivatives Drugs 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 101710019483 ebgA Proteins 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 101710034616 gVIII-1 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000002218 hypoglycaemic Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000002101 lytic Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003551 muscarinic Effects 0.000 description 2
- 101700045377 mvp1 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 102000035402 transmembrane proteins Human genes 0.000 description 2
- 108091005683 transmembrane proteins Proteins 0.000 description 2
- 230000001960 triggered Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 210000004404 Adrenal Cortex Anatomy 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229950006323 Angiotensin ii Drugs 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 229940114079 Arachidonic Acid Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100013472 CCK Human genes 0.000 description 1
- 101700066277 COS-1 Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 229940107137 Cholecystokinin Drugs 0.000 description 1
- 108010048926 Cholecystokinin Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000014750 EC 2.7.11.19 Human genes 0.000 description 1
- 108010064071 EC 2.7.11.19 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001272 Exogenous DNA Polymers 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- 108060003339 GPLD1 Proteins 0.000 description 1
- 210000001156 Gastric Mucosa Anatomy 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 229940045189 Glucose-6-Phosphate Drugs 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061992 Haemophilia Diseases 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108050003490 Insulin-like growth factor Proteins 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N Methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 Methoxyflurane Drugs 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- 102100009139 NGF Human genes 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N O(4)-phospho-L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 210000003681 Parotid Gland Anatomy 0.000 description 1
- 102000009569 Phosphoglucomutase Human genes 0.000 description 1
- 108010009450 Phosphoglucomutase Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 210000004198 Pituitary Gland, Anterior Anatomy 0.000 description 1
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 102000004278 Receptor protein-tyrosine kinases Human genes 0.000 description 1
- 108090000873 Receptor protein-tyrosine kinases Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043709 Thyroid disease Diseases 0.000 description 1
- 229940036555 Thyroid hormones Drugs 0.000 description 1
- 229940034208 Thyroxine Drugs 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 108010082685 antiarrhythmic peptide Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000001713 cholinergic Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 101700038984 csgA Proteins 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000002450 inherited metabolic disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 102000027634 intracellular receptors Human genes 0.000 description 1
- 108091007905 intracellular receptors Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 101710030587 ligN Proteins 0.000 description 1
- 101700077585 ligd Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 101500013277 mouse Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102000035329 multipass transmembrane proteins Human genes 0.000 description 1
- 108091005532 multipass transmembrane proteins Proteins 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001566 pro-viral Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 102000034377 signal transducing proteins Human genes 0.000 description 1
- 108091006008 signal transducing proteins Proteins 0.000 description 1
- 102000035331 single-pass transmembrane proteins Human genes 0.000 description 1
- 108091005534 single-pass transmembrane proteins Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N α-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical class C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Definitions
- the present invention relates to expression of a non-endogenous cell signalling receptor in a cell in order to gain control over a cellular function, and more particularly to the transformation of a cell with DNA encoding a non-endogenous cell signalling receptor that utilizes an endogenous signal transduction pathway in the cell, where the receptor can be controllably activated to regulate a cell function controlled by the signal transduction pathway.
- the differentiated function of a cell is defined, in part, by how it responds to its environment. While any given cell may be exposed to a myriad of signals, the specificity of cellular responses to extracellular regulatory molecules is modulated by the array of receptors present in that cell (1-5) . Interaction of an extracellular regulatory molecule with its cell signalling receptor leads to activation of one or more intracellular signal transduction pathways, eventuating in a response (s) specific for the cell. The specificity of the cellular response is dictated by the specific binding characteristics of the receptor and the specificity of the molecular targets downstream of the signal transduction cascade. In the same cell, a number of different receptors may use the identical signal transduction pathway and thus activation of different receptors can sometimes elicit similar responses (1-5) .
- the invention provides an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
- the invention also provides a method of ectopically expressing a non-endogenous receptor in a cell.
- the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
- the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
- the invention further provides a method of regulating a cell function in vivo .
- the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
- the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
- the in vivo cell is then controllably exposed to an extracellular molecule capable of activating the non-endogenous cell signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function controlled by the endogenous signal transduction pathway.
- the invention thus provides a method for controlling a cellular function using extracellular molecules which do not normally control the particular cellular function.
- Various malfunctions of cellular functions due to desensitization of an endogenous cellular receptor, or lack of or mutation of an endogenous cellular receptor, can thereby be overcome using the compositions and methods of the subject invention.
- Fig. 1 is a Northern analysis of RNA from in vi tro primary hepatocytes after incubation with adenovirus vectors, using a mouse TRH-R cDNA probe (lanes 1-6) or a human ⁇ -actin cDNA probe (lanes 7-12) ;
- Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone to hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA;
- Fig. 3 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA
- Fig. 4 is a Northern analysis of liver RNA with a mouse TRH-R cDNA probe after the animal received the AdCMV.j ⁇ gal vector (lane 1) or the AdCMV.mTRH-R vector (lane 2) in vivo;
- Fig. 5 is a Northern analysis of liver RNA with a ⁇ -actin cDNA probe after the animal received the AdCMV. ⁇ gal vector (lane 3) or the AdCMV.mTRH-R vector (lane 4) in vivo;
- Fig. 6 illustrates the binding of methyl- thyrotropin releasing hormone to primary hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo;
- Fig. 7 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo;
- Fig. 8 illustrates the modulation of serum glucose by TRH;
- Fig. 9 illustrates the average change in serum glucose levels.
- the subject invention provides a recombinant in vivo cell comprising an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
- the invention also provides a method of ectopically expressing a non-endogenous receptor in a cell.
- the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
- the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell .
- the invention further provides a method of regulating a cell function.
- the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
- the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
- the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
- the cell is then controllably exposed to an extracellular molecule capable of activating the cell signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function normally controlled by the endogenous signal transduction pathway.
- the in vivo cell to be transformed can be any suitable cell in which control over a cellular function is desired.
- the control is accomplished by transforming the cell with DNA encoding a cell signalling receptor not endogenous to the cell, and allowing the non-endogenous receptor to utilize an endogenous signal transduction pathway of the cell.
- Cellular functions influenced by the signal transduction pathway can thereby be controlled by controlling the activation of the non-endogenous receptor (i.e., by controlled exposure of the non- endogenous receptor to its extracellular signalling molecule) .
- the subject invention is best understood through a discussion of the various receptors and signal transduction pathways which can be utilized in accordance with the invention.
- Cells in higher animals normally communicate by means of hundreds of kinds of extracellular signalling molecules, including proteins, small peptides, amino acids, nucleotides, steroids, retinoids, fatty acid derivatives, and even dissolved gases such as nitric oxide and carbon monoxide.
- signalling molecules relay a "signal" to another cell (a "target cell”) , generally affecting a cellular function.
- target cell a cell in accordance with the subject invention, such extracellular signalling molecules are controllably administered or provided to a cell in vivo .
- the cell in vivo has been transformed so that the cell recognizes the extracellular signalling molecule via a non-endogenous receptor expressed by the cell.
- the non-endogenous receptor is specific for and binds the extracellular signalling molecule, and the presence of the non-endogenous receptor allows the in vivo cell to recognize the extracellular signalling molecule that it would not have recognized but for the presence of the non-endogenous receptor.
- the binding of the non-endogenous receptor to the extracellular signalling molecule then initiates a response in the transformed cell.
- these receptors for extracellular signalling molecules are collectively referred to as "cell signalling receptors”.
- cell signalling receptors are transmembrane proteins on the transformed cell surface; when they bind an extracellular signalling molecule (a ligand) , they become activated so as to generate a cascade of intracellular signals that alter the behavior of the cell.
- these receptors are collectively referred to as "cell surface signalling receptors".
- the receptors are inside the transformed cell and the signalling ligand has to enter the cell to activate them; these signalling molecules therefore must be sufficiently small and hydrophobic to diffuse across the plasma membrane of the cell.
- these receptors are collectively referred to as "intracellular cell signalling receptors" .
- Cell surface signalling receptors generally include three classes, defined by the transduction mechanism used. These are ion channel linked receptors, guanine nucleotide binding protein linked receptors, and enzyme linked receptors.
- Ion channel linked receptors also known as transmitter-gated ion channels, are involved in rapid synaptic signalling between electrically excitable cells. This type is signalling is mediated by a small number of extracellular signalling molecules known as neurotransmitters that transiently open or close the ion channel formed by the receptor protein to which they bind.
- the ion channel linked receptors belong to a family of homologous, multipass transmembrane proteins, and include ion channels for sodium, potassium, calcium, and chloride ions.
- Ion channels are not continuously open. Instead they have "gates", which open briefly and then close again. In most cases the gates open in response to a specific stimulus, such as the binding of a ligand (ligand-gated channels) .
- the ligand can be either an extracellular signalling molecule, specifically a neurotransmitter (transmitter-gated channels) , or an intracellular molecule, such as an ion (ion-gated channels) or a nucleotide (nucleotide-gated channels) .
- the second class of cell surface receptor proteins is the guanine nucleotide binding protein linked receptors . These receptors are also known as G protein linked receptors. These receptors act indirectly to regulate the activity of a separate plasma-membrane-bound target protein, which can be an enzyme or an ion channel. The interaction between the receptor and the target protein is mediated by a third protein, called a trimeric GTP-binding regulatory protein (G protein) .
- G protein GTP-binding regulatory protein
- the activation of the target protein either alters the concentration of one or more intracellular mediators (if the target protein is an enzyme) or alters the ion permeability of the plasma membrane (if the target protein is an ion channel) .
- the intracellular mediators act in turn to alter the behavior of yet other proteins in the cell. All of the G-protein-linked receptors belong to a large superfamily of homologous, seven-pass transmembrane proteins.
- G protein linked receptors are the largest family of cell surface receptors. More than 100 members have already been defined in mammals. G protein linked receptors mediate the cellular responses to an enormous diversity of signalling molecules, including hormones, neurotransmitters, and local mediators, which are as varied in structure as they are in function: the list includes proteins and small peptides, as well as amino acid and fatty acid derivatives. The same ligand can activate many different family members. At least 9 distinct G protein linked receptors are activated by adrenaline, for example, another 5 or more by acetylcholine, and at least 15 by serotonin.
- G protein linked receptors include, for example, the alpha-adrenergic receptors, the beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, peptidergic receptors, and the thyrotropin releasing hormone receptor.
- G protein linked receptors activate a chain of events that alters the concentration of one or more small intracellular signalling molecules. These small molecules, often referred to as intracellular mediators (also called intracellular messengers or second messengers) , in turn pass the signal on by altering the behavior of selected cellular proteins.
- intracellular mediators also called intracellular messengers or second messengers
- cAMP cyclic AMP
- Ca 2t changes in the concentrations are stimulated by distinct pathways in most animal cells, and most G-protein-linked receptors regulate one or the other of them.
- the third type of cell surface receptor proteins are the enzyme linked receptors which, when activated, either function directly as enzymes or are associated with enzymes. Most are single-pass transmembrane proteins, with their ligand-binding site outside the cell and their catalytic site inside. Compared with the other two classes, enzyme linked receptors are heterogeneous, although the great majority are protein kinases, or are associated with protein kinases, that phosphorylate specific sets of proteins in the target cell.
- transmembrane guanylyl cyclases which generate cyclic GMP directly
- receptor tyrosine phosphatases which remove phosphate from phosphotyrosine side chains of specific proteins
- transmembrane receptor serine/threonine kinases which add a phosphate group to serine and threonine side chains on target proteins
- receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
- receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
- receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
- receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
- receptor tyrosine kinases which add a phosphate group to serine and th
- receptors The last two types of receptors are by far the most numerous, and they are thought to work in a similar way: ligand binding usually induces the receptors to dimerize, which activates the kinase activity of either the receptor or its associated nonreceptor tyrosine kinase. When activated, receptor tyrosine kinases usually cross-phosphorylate themselves on multiple tyrosine residues, which then serve as docking sites for a small set of intracellular signaling proteins. In this way, a multiprotein signalling complex is activated from which the signal spreads to the cell interior.
- cell signalling is also accomplished via intracellular cell signalling receptors. As indicated above, these receptors are inside the target cell and the signalling ligand has to enter the cell to activate them.
- Steroid hormones, thyroid hormones, retinoids, and vitamin D are examples of small hydrophobic molecules that differ greatly from one another in both chemical structure and function.
- Steroid hormone receptors include progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors.
- Thyroid hormone receptors include the thyroid stimulating hormone receptor.
- Retinoid receptors include the receptor for retinoic acid.
- a cell is transformed with DNA encoding one or more of these cell signalling receptors which is not endogenous to the cell (which may be a cell surface signalling receptor or an intracellular cell signalling receptor) .
- the non-endogenous receptor is capable of activating a signal transduction pathway that is endogenous to the cell.
- a "non-endogenous" receptor is a receptor not normally present in/on (used interchangeably throughout this application) the particular cell. A receptor, therefore, may be non- endogenous to the transformed cell even though the receptor is present in/on other cells in the selected organism (i.e. in a human being) .
- a receptor present only in heart muscle tissue is a "non- endogenous" receptor in a liver cell.
- an "endogenous” pathway as used herein refers to a signal transduction pathway that is normally present in the transformed cell.
- ectopic expression as used herein refers to expression of a receptor in/on a particular cell in/on which the receptor is not normally present.
- “Eutopic” expression in contrast, is expression of a receptor in/on a particular cell in/on which the receptor is normally present.
- the DNA encoding the non-endogenous receptor is capable of activating an endogenous signal transduction pathway in the transformed cell.
- Signal transduction pathways are numerous, and include, for example, adenylate cyclase pathways, guanylate cyclase pathways, phosphoinositol turnover pathways, tyrosine kinase pathways, ion channel pathways, and calcium ion pathways.
- the initial signal produced by the binding of an extracellular signalling molecule to a cell signalling receptor is transduced intracellularly via a signal transduction pathway that may be multiple and interactive.
- Signal transduction pathways involve cAMP, cGMP, arachidonic acid, inositol 1,4, 5-tris-phosphate (IP 3 ) , Ca 2+ , and other ions as second messengers and are produced by enzymes (such as adenylate and guanylate cyclases and phospholipases A 2 and C) and ion channels.
- enzymes such as adenylate and guanylate cyclases and phospholipases A 2 and C
- an extracellular molecule-receptor complex does not interface directly with these effectors but acts via an intermediate modulating signal transducer, often a G protein.
- cAMP is the prototypical second messenger. Intracellular levels of cAMP are determined, in large part, by ligand-receptor interactions. This physiological event involves the interaction of three cellular components located near the plasma membrane: the ligand receptor, a signal transducer (G protein) , and the effector enzyme (adenylate cyclase) .
- Cyclic AMP is a second messenger for many hormones, including epinephrine, glucagon, norepinephrine, parathyroid and luteinizing hormones, and thyroid-stimulating and melanocyte-stimulating hormones.
- Cyclic AMP affects a wide range of cellular processes: increases lipolysis, glycogen degradation, gluconeogenesis, ketogenesis, ion permeability of epithelia, renin production by kidney, contraction of cardiac muscle, HCl secretion by the gastric mucosa, amylase release by the parotid gland, dispersion of melanin granules, and insulin release by the pancreas; decreases aggregation of platelets, and growth of tumor cells in tissue culture.
- the activation of adenyl cyclase leads to an increased amount of cyclic AMP inside the cell. Cyclic AMP then activates a protein kinase, which phosphorylates one or more proteins.
- glycogen synthetase and phosphorylase kinase results in decreased synthesis and enhanced degradation of glycogen.
- Table 1 classifies various hormone receptors and effectors according to the pathway utilized. Several receptors contain an intrinsic hormone-ac ivated tyrosine kinase activity.
- Guanylate cyclase catalyzes the formation of cGMP from GTP, in analogy with adenylate cyclase. Guanylate cyclase, however, exists in cells in both soluble and membrane-associated forms. The membrane- associated form is regulated by hormones and other ligands. Like the tyrosine kinases and unlike adenylate cyclase, guanylate cyclase may directly serve receptor and effector functions.
- a number of hormones and ligands mediate their cellular actions via calcium ions and DAG as second messengers.
- the second messengers modulate the activity of protein kinases regulated by calcium binding-regulatory protein (e.g. calmodulin) , and DAG activates protein kinase C.
- calmodulin calcium binding-regulatory protein
- DAG activates protein kinase C.
- These enzymes phosphorylate specific intracellular proteins, which results in further hormone action.
- Example of hormones using this signaling system in specific tissues include alpha-1-adrenergic and muscarinic cholinergic agents, vasopressin, histamine, cholecystokinin, LHRH, thyrotropin-releasing hormone, angiotensin II, and oxytocin.
- the various hormone ligands that stimulate phosphoinositide turnover interact with the receptors that activate G proteins, as described for adenylate cyclase. These activated G proteins, however, are coupled to stimulation of phospholipase C activity.
- thyroid-stimulating hormone TSH
- ACTH adrenocorticotropic hormone
- LH luteinizing hormone
- Atrial peptide also called atrial natriuretic factor
- Insulin-like growth factor somatomedin-C
- Alpha-adrenergic catecholamines Angiotensin
- Nerve growth factor T cell receptor Numerous cellular responses are mediated by G-protein-linked receptors coupled to the inositol- phospholipid signalling pathway, including: in the liver, the signalling molecule vasopressin induces glycogen breakdown; in the pancreas, the signalling molecule acetylcholine induces amylase secretion; in smooth muscle, the signalling molecule acetylcholine induces contraction; in mast cells, an antigen functions as a signalling molecule to induce histamine secretion; and in blood platelets, the signalling molecule thrombin induces aggregation.
- a method for transforming cells must also be selected.
- Various methods are known in the art.
- One of the first methods was microinjection, in which DNA was injected directly into the nucleus of cells through fine glass needles. This was an efficient process on a per cell basis, that is, a large fraction of the injected cells actually got the DNA, but only a few hundred cells could be injected in a single experiment.
- the earliest method for introducing DNA into cells en masse was to incubate the DNA with an inert carbohydrate polymer (dextran) to which a positively charged chemical group (DEAE, for diethylaminoethyl) had been coupled.
- the DNA sticks to the DEAE-dextran via its negatively charged phosphate groups.
- These large DNA-containing particles stick in turn to the surfaces of cells, which are thought to take them in by a process known as endocytosis.
- Some of the DNA evades destruction in the cytoplasm of the cell and escapes to the nucleus, where it can be transcribed into RNA like any other gene in the cell.
- the DEAE-dextran method while relatively simple, was very inefficient for many types of cells, so it was not a reliable method for the routine assay of the biological activity of a purified DNA preparation.
- the breakthrough that eventually made gene transfer a routine tool for workers studying mammalian cells was the discovery that cells efficiently took in DNA in the form of a precipitate with calcium phosphate. With this new method, the yield of virus from cells transfected with viral DNA was a hundred times greater than with the DEAE-dextran method.
- Biological markers can be used to identify the cells carrying recombinant DNA molecules. In bacteria, these are commonly drug-resistance genes. Drug resistance is used to select bacteria that have taken up cloned DNA from the much larger population of bacteria that have not.
- the transfer of exogenous DNA into cells was detected because the DNA had a biological activity, it led to production of infectious virus or produced stable changes in the growth properties of the transfected cells.
- the DNA tumor virus herpes simplex virus (HSV) , contained a gene encoding the enzyme thymidine kinase (the tk gene) .
- the HSV tk gene can be used as a selectable genetic marker in mammalian cells in much the same way that drug-resistance genes worked in bacteria, to allow rare transfected cells to grow up out of a much larger population that did not take up any DNA.
- the cells are transferred to selective growth medium, which permits growth only of cells that took up a functional tk gene (and the transferred DNA of interest) .
- Various dominant selectable markers are now known in the art, including: aminoglycoside phosphotransferase (APH) , using the drug G418 for selection which inhibits protein synthesis; the APH inactivates G418; dihydrofolate reductase (DHFR) :Mtx-resistant variant, using the drug methotrexate (Mtx) for selection which inhibits DHFR; the variant DHFR is resistant to Mtx; hygromycin-B-phosphotransferase (HPH) , using the drug hygromycin-B which inhibits protein synthesis; the HPH inactivates hygromycin B; thymidine kinase (TK) , using the drug aminopterin which inhibits de novo purine and thymidylate synthesis; the TK synthesizes thymidylate; xanthine-guanine phosphoribosyltransferase (XGPRT) , using the drug mycophenolic
- Gene amplification can also be used to obtain very high levels of expression of transfected gene.
- Mtx an inhibitor of a critical metabolic enzyme, DHFR
- DHFR a critical metabolic enzyme that kills cells.
- a gene to be expressed in cells is cotransfected with a cloned dhfr gene, and the transfected cells are subjected to selection with a low concentration of Mtx. Resistant cells that have taken up the dhfr gene (and, in most cases, the cotransfected gene) multiply. Increasing the concentration of Mtx in the growth medium in small steps generates populations of cells that have progressively amplified the dhfr gene, together with linked DNA.
- DNA can also be incorporated into artificial lipid vesicles, liposomes, which fuse with the cell membrane, delivering their contents directly into the cytoplasm.
- Microinjection the surest way to get DNA into cells, can now be performed with a computer- assisted apparatus that increases by 10-fold or more the number of cells that can be injected in one experiment.
- DNA is absorbed to the surface of tungsten microprojectiles and fired into cells with a device resembling a shotgun.
- naked DNA introduced by transfection can be transiently expressed in up to half the cells in a culture, more frequently the fraction of transiently transfected cells is much lower. In fact, some cells are almost completely refractory to transfection by the artificial methods described above.
- Many applications of recombinant DNA technology require introducing foreign genes (i.e. non-endogenous receptors) into recalcitrant cell types.
- Potential gene therapy strategies for example, require efficient means for transferring genes into normal human cells.
- viruses Viral growth depends on the ability to get the viral genome into cells, and viruses have devised clever and efficient methods for doing it . The earliest viral vectors, based on the monkey tumor virus SV40, simply substituted some of the viral genes with the foreign gene.
- recombinant molecules prepared as bacterial plasmids, were transfected into monkey cells together with a second plasmid that supplied the missing viral genes.
- viral gene products produced from the two plasmids cooperate to replicate both plasmids and package each into virus particles.
- the virus stock that emerges from the cell is a mixture of two viruses, each of which is by itself defective (that is, it cannot replicate on its own because it is missing necessary viral genes) . Nevertheless, this virus stock can then be used to infect new cells, efficiently introducing and expressing the foreign gene in the recipient cells.
- a hybrid method that uses transfection to get DNA into cells and a viral protein to replicate it once inside is now commonly used for high-level production of protein from a cloned gene.
- This procedure uses a cell line, COS cells, carrying a stably integrated portion of the SV40 genome. These cells produce the viral T antigen protein, which triggers replication of viral DNA by binding to a DNA sequence termed the origin of replication.
- the foreign gene to be expressed is cloned into a plasmid that carries the SV40 origin of replication. After transfection into COS cells, the plasmid is replicated to a very high number of copies, increasing the expression level of the foreign gene.
- SV-40-based viral vectors are limited for a number of reasons: they infect only monkey cells, the size of foreign gene that can be inserted is small, and the genomes are often rearranged or deleted. Other viral vectors are more commonly used now, either because they can infect a wider range of cells or because they accept a wider range of foreign genes.
- Vaccinia virus is a large DNA-containing virus that replicates entirely in the cytoplasm. Early vaccinia vectors incorporated the foreign gene directly into a nonessential region of the viral genome. Recombinant viruses are viable and upon infection transcribe the foreign gene from a nearby viral promoter.
- a more versatile vaccinia expression system uses a ready-made recombinant virus that expresses a bacteriophage RNA polymerase.
- the gene to be expressed is simply cloned into a plasmid carrying a bacteriophage promoter.
- the plasmid is transfected into cells that have been previously infected with the vaccinia virus that expresses the RNA polymerase.
- the gene on the plasmid is efficiently transcribed by the bacteriophage polymerase, accounting for up to 30 percent of the RNA in the cell.
- An additional feature of vaccinia virus infection is that the virus shuts down host cell protein synthesis so that viral mRNA (and mRNA from the plasmid) are preferentially translated into protein.
- Baculovirus Another virus widely used for protein production is an insect virus, baculovirus.
- Baculovirus attracted the attention of researchers because during infection, it produces one of its structural proteins (the coat protein) to spectacular levels. If a foreign gene were to be substituted for this viral gene, it too ought to be produced at high levels.
- Baculovirus like vaccinia, is very large, and therefore foreign genes must be placed in the viral genome by recombination.
- the gene of interest is cloned in place of the viral coat protein gene in a plasmid carrying a small portion of the viral genome. The recombinant plasmid is cotransfected into insect cells with wild ⁇ type baculovirus DNA.
- the plasmid and viral DNAs recombine through homologous sequences, resulting in the insertion of the foreign gene into the viral genome.
- Virus plaques develop, and the plaques containing recombinant virus look different because they lack the coat protein.
- the plaques with recombinant virus are picked and expanded. This virus stock is then used to infect a fresh culture of insect cells, resulting in high expression of the foreign protein.
- baculovirus vectors see reference (51) .
- Retroviruses are RNA viruses with a life cycle quite different from that of the lytic viruses. When they infect cells, their RNA genomes are converted to a DNA form (by the viral enzyme reverse transcriptase) . The viral DNA is efficiently integrated into the host genome, where it permanently resides, replicating along with host DNA at each cell division. This integrated provirus steadily produces viral RNA from a strong promoter located at the end of the genome (in a sequence called the long terminal repeat or LTR) .
- LTR long terminal repeat
- This viral RNA serves both as mRNA for the production of viral proteins and as genomic RNA for new viruses. Viruses are assembled in the cytoplasm and bud from the cell membrane, usually with little effect on the cell's health. Thus, the retrovirus genome becomes a permanent part of the host cell genome, and any foreign gene placed in a retrovirus ought to be expressed in the cells indefinitely.
- Retroviruses are therefore attractive vectors because they can permanently express a foreign gene in cells. Moreover, they can infect virtually every type of mammalian cell, making them exceptionally versatile. Because of their versatility, retroviruses are also the vector of choice for gene therapy. In the design and use of retroviral vectors, the vectors usually contain a selectable marker as well as the foreign gene to be expressed. Most of the viral structural genes are gone, so these vectors cannot replicate as viruses on their own. To prepare virus stocks, cloned proviral DNA is transfected into a packaging cell. These cells usually contain an integrated provirus with all its genes intact, but lacking the sequence recognized by the packaging apparatus.
- the packaging provirus produces all the proteins required for packaging of viral RNA into infectious virus particles but it cannot package its own RNA. Instead, RNA transcribed from the transfected vector is packaged into infectious virus particles and released from the cell. The resulting virus stock is termed helper-free because it lacks wild-type replication-competent virus. This virus stock can be used to infect a target cell culture.
- the recombinant genome is efficiently introduced, reverse- transcribed into DNA (by reverse transcriptase deposited in the virus by the packaging cells) , and integrated into the genome.
- the cells now express the new virally introduced gene, but they never produce any virus, because the recombinant virus genome lacks the necessary viral genes.
- retrovirus vectors see references (52,53) .
- Another viral vector is adenovirus, reviewed by Berkner, K.L. (54) .
- Still another viral vector is herpesvirus.
- U.S. Patent No. 4,237,224 to Cohen and Boyer describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture. The DNA sequences are cloned into the plasmid vector using standard cloning procedures in the art, as described by Maniatis et al . , Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1982) .
- a transformed cell containing a foreign gene of interest i.e., a non-endogenous receptor
- the cell may be transformed in vi tro and reinserted into a multicellular organism, or the cell may be transformed in vivo .
- a retrovirus acts as a vector to carry a gene into a cell, so the cell can be regarded as a vector for carrying the gene into a patient's body.
- Suitable cells for transformation and use in gene therapy should be readily obtainable, grow well in culture, and be able to withstand the various manipulations involved in, for example, retrovirus or adenovirus infection.
- vector cells should be easy to return to the patient after such transformation and should continue to live for many months, preferably for the life of the patient. See Friedmann (55) , Verma (56) , Anderson (62) and Mulligan (63) for discussions of gene therapy.
- the cells of the bone marrow have many of these desirable features.
- the bone marrow contains stem cells that give rise to all cells of the hematopoietic series. Infection of these stem cells results in a continuous supply of cells containing the therapeutic gene.
- the techniques for reconstituting the bone marrow of patients and experimental animals are well worked out .
- Convincing evidence that genes introduced in hematopoietic stem cells are expressed and that they can produce a therapeutic effect has come from experiments with a mutant dihydrofolate reductase gene (DHFR) .
- DHFR dihydrofolate reductase gene
- Another cell type that has been studied intensively as a vehicle for gene transfer is the skin fibroblast. Fibroblasts are easily obtainable, grow well in culture, and have been the subjects of many experiments, and skin fibroblasts can be efficiently infected with viral vectors, such as retroviral vectors. See Palmer et al . (58) .
- liver Another target tissue for gene therapy is the liver.
- Techniques have been developed for isolating and culturing hepatocytes, so the appropriate target cells are available for viral-mediated gene transfer. See Anderson et al . (59) .
- suitable cells to be transformed according to the subject invention include, for example, a liver cell (known as a hepatocyte) in which one desires to control glycogenolysis.
- a liver cell known as a hepatocyte
- This can be accomplished by transforming the liver cell with DNA encoding a cell signalling receptor not endogenous to the cell (i.e. not normally present on the liver cell), where the receptor is capable of activating a signal transduction pathway endogenous (i.e. normally present in the cell) to the liver cell.
- the non-endogenous receptor is chosen such that the compatible signal transduction pathway regulates glycogenolysis in the cell.
- the cAMP pathway and phosphoinositide pathways within the liver cell regulate glycogenolysis, and DNA encoding a thyrotropin releasing hormone receptor (a receptor not endogenous to the liver cell) can be transformed into the liver cell to activate these two endogenous pathways, thereby providing for controllable activation of the pathways (by introducing an extracellular molecule capable of binding to the non-endogenous receptor and thereby stimulating the endogenous pathway) .
- a liver cell is one example of a suitable in vivo cell according to the subject invention.
- Other cells are equally transformable, such as cells of the pulmonary airways. These cells can be transformed with a thyroid-stimulating hormone receptor which can utilize the pulmonary airways' endogenous cyclic AMP signal transduction pathway. Extracellular molecules capable of activating the thyroid-stimulating hormone receptor would therefore control the same cellular function as do adrenergic agonists and bronchodilating drugs (which utilize the cAMP pathway to normally control cellular function) .
- Adenovirus-based vectors to transform liver cells.
- Adenovirus based vectors have been used successfully to express a number of mammalian and viral proteins but they have not been used to ectopically express cell signalling receptors in vivo.
- the following examples show that functions of a specific cell type can be regulated in an intact animal by an agonist that does not usually affect functions in this cell type (because the cell does not endogenously express the receptor for this agonist) when the receptor for this agonist is expressed by adenovirus-mediated gene transfer. This is so because the expressed non-endogenous receptor couples to an endogenous signal transduction pathway and thereby regulates cell function.
- TRH neurohormone thyrotropin-releasing hormone
- This invention has important therapeutic applications. These applications include temporary relief of life-threatening illnesses, with receptor expression in diseased tissues and in tissues unaffected by the disease process.
- An example of an application in a diseased tissue would be the expression of the receptor for thyroid-stimulating hormone in pulmonary airways to mediate, via an elevation of cyclic AMP, which is the same pathway used by adrenergic agonists and bronchodilating drugs, a bronchodilatory response in patients with chronic obstructive pulmonary disease or asthma suffering a marked exacerbation.
- a therapeutic advantage of using more than one receptor to mediate the desired response is that the efficacy of most drugs decreases upon repeated administrations, a process termed tachyphylaxis, which is usually caused by receptor desensitization.
- tachyphylaxis which is usually caused by receptor desensitization.
- Another application is for the treatment of diseases for which regulation of a physiologic function in a healthy organ would counter-balance the effects of a disease process.
- An example of this is presented in the Examples which follow, in which blood glucose was elevated by TRH after etopic expression of TRH receptors in liver.
- This approach can be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) to maintain normoglycemia over an extended period of time.
- glycogenolysis Maintenance of blood glucose by glycogenolysis in the liver is normally initiated by extracellular regulatory molecules such as glucagon and vasopressin triggering specific receptors on hepatocytes to activate the cAMP or phosphoinositide signal transduction pathways.
- the subject invention demonstrates that the normal ligand-receptor regulators of glycogenolysis can be bypassed using an adenovirus vector to ectopically express the non-endogenous mouse pituitary thyrotropin releasing hormone receptor
- TRH-R cDNA in rat liver in vivo .
- the ectopically expressed TRH-R links to the phosphoinositide pathway, providing a means to activate glycogenolysis with TRH, an extracellular ligand not normally associated with liver physiology.
- TRH is administered to these animals, the phosphoinositide path is activated resulting in a sustained rise in blood glucose.
- the invention provides an approach to the therapy of such disorders which is to bypass the normal extracellular regulatory molecule and its specific endogenous receptor by using an alternative ligand and non-endogenous receptor to trigger the relevant endogenous signal transduction pathway.
- Such a strategy can be used to correct abnormalities of extracellular regulatory molecules or their specific endogenous receptors, as well as to modulate specific physiologic functions in disease states by re-establishing control of specific signal transduction pathways.
- the subject invention provides a new strategy to specifically control the differentiated function of cells in vivo by providing the means to trigger a specific signal transduction pathway by using a gene transfer vector to ectopically express a naturally occurring receptor in cells of an organ that do not normally express that receptor (i.e. a non-endogenous receptor) .
- the expressed receptor links to its natural signal transduction pathway, enabling specific responses to be triggered in the target cells by a ligand relevant for that receptor.
- TRH thyrotropin- releasing hormone
- TRH-R thyrotropin- releasing hormone receptor
- TRH-Rs in pituitary cells are stimulated by TRH
- the TRH-R triggers, via a guanine nucleotide binding protein, the phosphoinositide-calcium-protein kinase C signal transduction pathway and the pituitary releases thyroid stimulating hormone (TSH) (2,13,14) .
- TSH thyroid stimulating hormone
- triggering of the phosphoinositide pathway in hepatocytes results not in TSH release, but in glycogen breakdown and the release of glucose into the circulation (5) .
- the subject invention provides for the transfer and expression of the TRH-R cDNA in hepatocytes in vivo with linkage of the expressed receptor to the hepatocyte phosphoinositide pathway. Therefore, systemic administration of TRH to animals expressing TRH receptors in the liver triggers the phosphoinositide pathway in hepatocytes, resulting in a rise in blood glucose.
- the parent plasmid, pAdCMV.mTRH-R was constructed by inserting a 1.2 kb EcoRI -NotI fragment containing the protein-coding region of the mouse TRH-R cD ⁇ A, nucleotides 233-1462 of plasmid pBSmTRHR (43) , into plasmid pGEM2-L3-114 at the EcoRI-BamHI site.
- Hindlll linkers were ligated and a 1.4 kb Hindlll fragment containing mouse TRH-R cD ⁇ A and the adenovirus E2 poly(A) signal sequence was isolated and inserted into the Hindlll site of the pAdCMV-HS-Vector which contains the left end replication and packaging elements of adenovirus, the cytomegalovirus-1 promoter and splicing elements from plasmid pML-IS Cat (44) .
- the virus AdCMV.mTRH-R was constructed by overlap recombination as described by Tantravahi et al . (45) . All transfections were carried out in human embryonic kidney cells transformed with the El region of adenovirus type 5 according to the procedure of Graham et al . (46) . Following plaque purification, virus was grown in 293 cells in suspension cultures as described by Tantravahi et al . (45) .
- pAdCMV.mTRH-R The construction of the recombinant plasmid designated pAdCMV.mTRH-R and the adenovirus vector designated AdCMV.mTHR-R is described fully by Gershengorn et al. (10) and Falck-Pedersen et al . (30) .
- AdCMV.mTRH-R The ability of AdCMV.mTRH-R to transfer and express the mouse TRH-R cDNA in rat hepatocytes was first demonstrated in vi tro .
- the replication-deficient recombinant adenovirus vectors are all Ela " , partial Elb " , partial E3 " based on adenovirus type 5, in which an expression cassette containing a promoter, driving the expression of a recombinant gene, is inserted at the site of the El deletion.
- AdCMV.mTRH-R contains an expression cassette with the cytomegalovirus early intermediate promoter/enhancer (CMV) followed by the mouse thyrotropin releasing hormone receptor (TRH-R) cDNA (30) .
- CMV cytomegalovirus early intermediate promoter/enhancer
- TRH-R mouse thyrotropin releasing hormone receptor
- AdCMV.jSgal carries the CMV promoter and the E. coli LacZ gene [encoding /S-galactosidase (3gal)] (31) .
- the adenovirus vectors were prepared, purified, and titered as previously described (32,33) .
- Primary hepatocyte cultures established from 250-300 g male Sprague-Dawley rats (19) , were exposed to AdCMV.mTRH-R at different multiplicity of infection (moi, 1, 10, 50, 100) ; uninfected cells and cells infected with AdCMV. / 3gal (moi 50) were used as controls.
- RNA (10 ⁇ g/lane) from primary hepatocytes was evaluated 24 hr after incubation with the vectors using a mouse
- TRH-R cDNA probe (lanes 1-6) , or as a positive control, human ⁇ -actin cDNA probe (lanes 7-12) .
- the sizes of the transcripts are indicated.
- Incubation of the hepatocytes with AdCMV.mTRH-R resulted in a dose-dependent expression of TRH-R mRNA transcripts
- hepatocytes that were uninfected or infected with the control vector AdCMV. ⁇ gal demonstrated no TRH-R mRNA transcripts (see Fig. 1, lanes 1 and 2) , although control ⁇ -actin mRNA transcripts were similar in all samples (see Fig. 1, lanes 7-12) .
- Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone (methyl-TRH) to hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA.
- methyl-TRH methyl- thyrotropin releasing hormone
- the hepatocytes (10 6 /well) were incubated for 60 min with [ 3 H] methyl-TRH (82.5 Ci/mmol, New England Nuclear-Dupont, Boston, MA) or [ 3 H]methyl-TRH plus excess unlabeled methyl-TRH (Sigma, St. Louis, MO) .
- Free ligand was removed by aspirating the medium and washing the cells 5 times with 2 ml (4°C) Hanks balanced salt solution. Cell associated radioactivity was measured by dissolving the cells with 1 ml of 0.4 N NaOH and counting.
- Fig. 3 shows the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA.
- Primary hepatocytes were exposed to the vectors AdCMV. / 3gal or AdCMV.mTRH-R. After 24 hr, the cells were labeled for 24 hr with myo- [ 3 H] inositol (myo- [2-
- inositol 20 Ci/mmol, Amersham Corporation, Arlington Heights, IL
- incubated 5 min, 37°C
- 10 mM LiCl stimulated (60 min, 37°C) with methyl-TRH.
- the cells were then lysed, the inositol phosphates were separated by anion-exchange chromatography and the radioactivity counted.
- the fold stimulation of inositol phosphates formation was calculated as: (dpm in inositol phosphates x 100/dpm in lipids of stimulated cells) - (dpm in inositol phosphates x 100/dpm in lipids of unstimulated cells) (35) .
- triplicate measurements were made in hepatocytes from two different animals.
- the AdCMV.mTRH-R vector effectively transferred the TRH-R cDNA to the rat liver in vivo, with the consequent ectopic expression of functional TRH-Rs in the hepatocytes.
- the AdCMV.mTRH-R was administered intravenously to the animals, a route of administration of replication deficient adenovirus vectors that results in > 90% detected expression of the exogenous gene in hepatocytes (16) .
- AdCMV.mTRH-R AdCMV.jSgal
- AdCMV.Null the "Null" vector is similar to the other vectors except that the expression cassette contains the CMV promoter but no recombinant gene) (31)] were administered via the right external jugular vein (5xl0 9 pfu, 100 ⁇ l 0.9% NaCl) .
- the livers were recovered 5 days later.
- Figs. 4 and 5 are Northern analyses. Liver RNA (10 ⁇ g/lane) was evaluated with a mouse TRH-R cDNA probe (Fig. 4, lanes 1 and 2) or, as a positive control, ⁇ -actin cDNA (Fig. 5, lanes 3 and 4) . The sizes of the transcripts are indicated. Lanes 1 and 3 (Fig. 4 and Fig. 5, respectively) are animals receiving AdCMV. / Sgal. Lanes 2 and 4 (Fig.
- Fig. 4 and Fig. 5, respectively are animals receiving AdCMV.mTRH-R.
- Northern analysis of hepatocytes obtained from animals receiving the control vector AdCMV. / Sgal demonstrated no TRH-R mRNA specific transcripts (Fig. 4, lane 1 and Fig. 5, lane 3) .
- hepatocytes obtained from AdCMV.mTRH-R infected animals showed TRH-R mRNA transcripts of the expected size (see Fig. 4, lane 2) .
- ⁇ -actin mRNA transcripts were observed in all samples.
- hepatocytes recovered from animals receiving AdCMV.mTRH-R in vivo demonstrated high levels of methyl-TRH specific binding, whereas no specific methyl-TRH binding was observed in naive animals or animals receiving the control vector AdCMV. / Sgal (Fig. 6) .
- the analysis of [ 3 H]methyl-TRH binding was identical to that described for Fig. 2. Triplicate measurements were made from three individual animals per condition.
- the hepatocytes derived from the AdCMV.mTRH-R infected animals demonstrated 6. lxlO 5 TRH-R receptors/cells, with a Kd of 2.51 ⁇ 0.32 nM.
- the methyl-TRH complex underwent internalization in hepatocytes from AdCMV.mTRH-R infected animals (not shown) .
- the liver maintains blood glucose levels by secreting glucose derived from hepatocyte glycogen stores into the circulation. This process is regulated by specific cell-surface receptors activating either of two signal transduction pathways, the cAMP pathway or the phosphoinositide pathway. Both converge to activate phosphorylase B which cleaves glycogen to glucose-1-phosphate, which is then isomerized to glucose-6-phosphate by phosphoglucomutase, and finally dephosphorylated by glucose-6-phosphatase to glucose which is secreted (17) .
- This example discloses the modulation in levels of serum glucose by TRH in animals following in vivo transfer of the TRH-R cDNA to the liver.
- the vectors AdCMV.mTRH-R or AdCMV.Null (5xl0 9 pfu) , or saline (0.9%) as negative control (all in 100 ⁇ l) were administered to rats as described above.
- the animals were anaesthetized by methoxyflurane (Pitman-Moore, Mundelein, IL) inhalation and the left and right external jugular veins were cannulated. After 15 min to permit stabilization, a 15 min baseline period was started, during which serum samples for glucose levels were obtained every 5 min.
- methyl-TRH 500 ⁇ g in 100 ⁇ l or saline (0.9%, 100 ⁇ l) was administered in one cannula and the serum samples obtained from the other cannula every 5 min for 55 min. Serum glucose levels were determined by colormetric assay (Sigma Diagnostics, St. Louis, MO) .
- Fig. 8 illustrates the modulation of serum glucose by TRH.
- the baseline glucose levels were determined for each animal as an average from -15 to 0 before administration of methyl-TRH or saline.
- the data are presented as the absolute change from the average baseline serum glucose level (mM) using each individual animal as its own control, and averaging the values at each time point for each group of animals.
- the data is presented as the mean for all animals in the group at each time point.
- the normal range for serum glucose Sprague-Dawley rats is 2.5 - 6.7 mM(36) .
- the average baseline values (mean ⁇ standard deviation) were: AdCMV.mTRH-R(IV) /TRH group 6.1 ⁇ 0.8 mM; AdCMV.mTRH-R(IP) /TRH group 5.6 ⁇ 0.5 mM; AdCMV.Null (IV) /TRH group 4.6 ⁇ 0.5 mM;
- Fig. 9 illustrates the average change in serum glucose levels from baseline.
- the average change in serum glucose levels from baseline was determined for each time point from 15 to 55 min after administration of methyl-TRH or saline on day 5.
- the data are presented as mean + standard deviation. All statistical comparisons were made using the two-tailed Student's t-test.
- Direct support for the concept that the liver was responsible for the rise in blood glucose came from administration of the AdCMV.mTRH-R vector to rats via the portal vein [a route of administration of an adenovirus vector to rats known to result in limitation of vector gene expression only in hepatocytes (19,20)] , followed 5 days later by the administration of intravenous methyl-TRH.
- the present invention supports the concept that ectopic expression of a non-endogenous naturally occurring receptor can be used to control differentiated functions of cells in vivo, using the natural ligand for the receptor to activate the receptor, and in turn, activate a specific signal transduction pathway in the cell, thus triggering a cell-specific response.
- the strategy can be used as an alternative means to modulate specific differentiated functions of cells using naturally occurring ligands or receptor-specific drugs and their corresponding receptors not normally relevant to that cell type.
- the strategy of expressing natural receptors as described herein adds to a growing list of strategies to modify receptor number and/or function, including overexpression of natural receptors in their natural location (21) and "designer" receptors that respond to artificial ligands (22) as means of triggering specific signal transduction pathways to activate specific differentiated functions of cells, and the transfer of normal receptors to their normal location to compensate for mutations in the natural receptor (23,24) .
- Clinical applications of this strategy include activation of differentiated functions that are impotent and/or dysfunctional secondary to inherited or acquired abnormalities associated with signalling molecules or their specific receptors.
- a strategy could be used to bypass acquired ligand deficiency states associated with antibodies directed against the ligand, such as observed in individuals with diabetes receiving insulin of human and non-human origin, polyclonal anti-insulin antibodies in individuals with various autoimmune disorders and anti- thyroxine antibodies in patients with immune thyroid disease and plasma cell dyscrasias (1,6,7) .
- receptor-specific autoantibodies intercept the ability of extracellular regulatory molecules to interact with their specific receptors, including the autoantibodies against ⁇ l-adrenergic receptors implicated in the pathogenesis of idiopathic dilated cardiomyopathy and the cardiomyopathy associated with Chagas' disease, autoantibodies against ⁇ 2 -adrenergic receptors linked to the pathogenesis of some forms of asthma, antibodies to the insulin receptor associated with the diabetes found and type B insulin resistance observed in individuals with acanthosis nigricans and ataxia telangiectasia, autoantibodies to the acetylcholine receptor in myasthenia gravis and to the glutamate receptor in Rasmussen's encephalitis (1,6,7,27,28) .
- this strategy may also be applied to the treatment of diseases for which regulation of a physiologic function in a healthy organ would counterbalance the effects of a disease process.
- An example of this is suggested by the previous examples, in which blood glucose was elevated by TRH after ectopic expression of TRH-Rs in liver.
- This approach could be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) in order to maintain normoglycemia over an extended period of time (29) .
Abstract
The present invention is directed to an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway. The invention also provides a method of ectopically expressing a non-endogenous receptor in a cell, and a method of regulating a cell function in vivo. The method of regulating a cell function comprises transforming a cell with DNA encoding a cell signalling receptor not endogenous to the cell, as above, and controllably exposing the cell to an extracellular molecule capable of activating the foreign cell signalling receptor. Activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function controlled by the endogenous signal transduction pathway.
Description
REGULATION OF CELLULAR FUNCTIONS BY ECTOPIC EXPRESSION OF NON-ENDOGENOUS CELL SIGNALLING RECEPTORS
The subject matter of this application was made with support from the United States Government (National Institute of Health Grant No. ROl DK43036) .
FIELD OF THE INVENTION The present invention relates to expression of a non-endogenous cell signalling receptor in a cell in order to gain control over a cellular function, and more particularly to the transformation of a cell with DNA encoding a non-endogenous cell signalling receptor that utilizes an endogenous signal transduction pathway in the cell, where the receptor can be controllably activated to regulate a cell function controlled by the signal transduction pathway.
BACKGROUND OF THE INVENTION
Throughout this application various publications are referenced, many in parenthesis. Full citations for these publications are provided at the end of the Detailed Description. The disclosures of these publications in their entireties are hereby incorporated by reference in this application.
The differentiated function of a cell is defined, in part, by how it responds to its environment. While any given cell may be exposed to a myriad of signals, the specificity of cellular responses to extracellular regulatory molecules is modulated by the array of receptors present in that cell (1-5) . Interaction of an extracellular regulatory molecule with its cell signalling receptor leads to activation of one or more intracellular signal transduction pathways, eventuating in a response (s) specific for the cell. The specificity of the cellular
response is dictated by the specific binding characteristics of the receptor and the specificity of the molecular targets downstream of the signal transduction cascade. In the same cell, a number of different receptors may use the identical signal transduction pathway and thus activation of different receptors can sometimes elicit similar responses (1-5) . There are a number of inherited and acquired human disorders in which the disease phenotype can be corrected, or at least alleviated, if a particular signal transduction pathway could be activated in a specific cell/tissue in a controlled or regulated fashion. A general application of this approach would be activation of a signalling cascade to inhibit a process that has become overly stimulated in disease or to stimulate a cellular response that had been inhibited by disease. In these cases, the pathogenesis of the disease does not involve the specific signalling pathway. The disease phenotype would be overcome by other cellular responses triggered by a non-endogenous receptor. A specific application of this approach is in disorders in which there is dysregulation of differentiated functions secondary to abnormalities associated with extracellular regulatory molecules or their specific receptors. In these cases, the non- endogenous receptor could be employed to trigger the signalling pathway that had been disrupted by the disease.
SUMMARY OF INVENTION
To this end, it is an object of the subject invention to provide a method to regulate the function of a diseased or normal cell/tissue so as to produce a response in the cell/tissue that would overcome or
alleviate a diseased phenotype in that or in another cell/tissue.
More particularly, the invention provides an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
The invention also provides a method of ectopically expressing a non-endogenous receptor in a cell. The method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell. The cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
The invention further provides a method of regulating a cell function in vivo . The method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell. The cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell. The in vivo cell is then controllably exposed to an extracellular molecule capable of activating the non-endogenous cell
signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function controlled by the endogenous signal transduction pathway.
The invention thus provides a method for controlling a cellular function using extracellular molecules which do not normally control the particular cellular function. Various malfunctions of cellular functions due to desensitization of an endogenous cellular receptor, or lack of or mutation of an endogenous cellular receptor, can thereby be overcome using the compositions and methods of the subject invention.
BRIEF DESCRIPTION OF THE DRAWINGS These and other features and advantages of this invention will be evident from the following detailed description of preferred embodiments when read in conjunction with the accompanying drawings in which:
Fig. 1 is a Northern analysis of RNA from in vi tro primary hepatocytes after incubation with adenovirus vectors, using a mouse TRH-R cDNA probe (lanes 1-6) or a human γ-actin cDNA probe (lanes 7-12) ; Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone to hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA;
Fig. 3 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA;
Fig. 4 is a Northern analysis of liver RNA with a mouse TRH-R cDNA probe after the animal received
the AdCMV.jβgal vector (lane 1) or the AdCMV.mTRH-R vector (lane 2) in vivo;
Fig. 5 is a Northern analysis of liver RNA with a γ-actin cDNA probe after the animal received the AdCMV.βgal vector (lane 3) or the AdCMV.mTRH-R vector (lane 4) in vivo;
Fig. 6 illustrates the binding of methyl- thyrotropin releasing hormone to primary hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo;
Fig. 7 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo; Fig. 8 illustrates the modulation of serum glucose by TRH; and
Fig. 9 illustrates the average change in serum glucose levels.
DETAILED DESCRIPTION
The subject invention provides a recombinant in vivo cell comprising an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
The invention also provides a method of ectopically expressing a non-endogenous receptor in a cell. The method comprises selecting a cell for transformation with DNA encoding a cell signalling
receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell. The cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell .
The invention further provides a method of regulating a cell function. The method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell. The cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell. The cell is then controllably exposed to an extracellular molecule capable of activating the cell signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function normally controlled by the endogenous signal transduction pathway.
The in vivo cell to be transformed can be any suitable cell in which control over a cellular function is desired. The control is accomplished by transforming the cell with DNA encoding a cell signalling receptor not endogenous to the cell, and allowing the non-endogenous receptor to utilize an endogenous signal transduction pathway of the cell. Cellular functions influenced by the signal transduction pathway can thereby be controlled by controlling the activation of the non-endogenous receptor (i.e., by controlled exposure of the non-
endogenous receptor to its extracellular signalling molecule) .
The subject invention is best understood through a discussion of the various receptors and signal transduction pathways which can be utilized in accordance with the invention. Cells in higher animals normally communicate by means of hundreds of kinds of extracellular signalling molecules, including proteins, small peptides, amino acids, nucleotides, steroids, retinoids, fatty acid derivatives, and even dissolved gases such as nitric oxide and carbon monoxide. These signalling molecules relay a "signal" to another cell (a "target cell") , generally affecting a cellular function. In accordance with the subject invention, such extracellular signalling molecules are controllably administered or provided to a cell in vivo . The cell in vivo has been transformed so that the cell recognizes the extracellular signalling molecule via a non-endogenous receptor expressed by the cell. The non-endogenous receptor is specific for and binds the extracellular signalling molecule, and the presence of the non-endogenous receptor allows the in vivo cell to recognize the extracellular signalling molecule that it would not have recognized but for the presence of the non-endogenous receptor. The binding of the non-endogenous receptor to the extracellular signalling molecule then initiates a response in the transformed cell. As used herein, these receptors for extracellular signalling molecules are collectively referred to as "cell signalling receptors".
Many cell signalling receptors are transmembrane proteins on the transformed cell surface; when they bind an extracellular signalling molecule (a ligand) , they become activated so as to generate a
cascade of intracellular signals that alter the behavior of the cell. As used herein, these receptors are collectively referred to as "cell surface signalling receptors". In some cases, the receptors are inside the transformed cell and the signalling ligand has to enter the cell to activate them; these signalling molecules therefore must be sufficiently small and hydrophobic to diffuse across the plasma membrane of the cell. As used herein, these receptors are collectively referred to as "intracellular cell signalling receptors" .
Cell surface signalling receptors generally include three classes, defined by the transduction mechanism used. These are ion channel linked receptors, guanine nucleotide binding protein linked receptors, and enzyme linked receptors.
Ion channel linked receptors, also known as transmitter-gated ion channels, are involved in rapid synaptic signalling between electrically excitable cells. This type is signalling is mediated by a small number of extracellular signalling molecules known as neurotransmitters that transiently open or close the ion channel formed by the receptor protein to which they bind. The ion channel linked receptors belong to a family of homologous, multipass transmembrane proteins, and include ion channels for sodium, potassium, calcium, and chloride ions.
Ion channels are not continuously open. Instead they have "gates", which open briefly and then close again. In most cases the gates open in response to a specific stimulus, such as the binding of a ligand (ligand-gated channels) . The ligand can be either an extracellular signalling molecule, specifically a neurotransmitter (transmitter-gated channels) , or an
intracellular molecule, such as an ion (ion-gated channels) or a nucleotide (nucleotide-gated channels) .
The second class of cell surface receptor proteins is the guanine nucleotide binding protein linked receptors . These receptors are also known as G protein linked receptors. These receptors act indirectly to regulate the activity of a separate plasma-membrane-bound target protein, which can be an enzyme or an ion channel. The interaction between the receptor and the target protein is mediated by a third protein, called a trimeric GTP-binding regulatory protein (G protein) . The activation of the target protein either alters the concentration of one or more intracellular mediators (if the target protein is an enzyme) or alters the ion permeability of the plasma membrane (if the target protein is an ion channel) . The intracellular mediators act in turn to alter the behavior of yet other proteins in the cell. All of the G-protein-linked receptors belong to a large superfamily of homologous, seven-pass transmembrane proteins.
G protein linked receptors are the largest family of cell surface receptors. More than 100 members have already been defined in mammals. G protein linked receptors mediate the cellular responses to an enormous diversity of signalling molecules, including hormones, neurotransmitters, and local mediators, which are as varied in structure as they are in function: the list includes proteins and small peptides, as well as amino acid and fatty acid derivatives. The same ligand can activate many different family members. At least 9 distinct G protein linked receptors are activated by adrenaline, for example, another 5 or more by acetylcholine, and at
least 15 by serotonin. G protein linked receptors include, for example, the alpha-adrenergic receptors, the beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, peptidergic receptors, and the thyrotropin releasing hormone receptor.
Most G protein linked receptors activate a chain of events that alters the concentration of one or more small intracellular signalling molecules. These small molecules, often referred to as intracellular mediators (also called intracellular messengers or second messengers) , in turn pass the signal on by altering the behavior of selected cellular proteins. Two of the most widely used intracellular mediators are cyclic AMP (cAMP) and Ca2t : changes in the concentrations are stimulated by distinct pathways in most animal cells, and most G-protein-linked receptors regulate one or the other of them.
The third type of cell surface receptor proteins are the enzyme linked receptors which, when activated, either function directly as enzymes or are associated with enzymes. Most are single-pass transmembrane proteins, with their ligand-binding site outside the cell and their catalytic site inside. Compared with the other two classes, enzyme linked receptors are heterogeneous, although the great majority are protein kinases, or are associated with protein kinases, that phosphorylate specific sets of proteins in the target cell. There are five known classes of enzyme-linked receptors: (1) transmembrane guanylyl cyclases, which generate cyclic GMP directly; (2) receptor tyrosine phosphatases, which remove phosphate from phosphotyrosine side chains of specific proteins; (3)
transmembrane receptor serine/threonine kinases, which add a phosphate group to serine and threonine side chains on target proteins; (4) receptor tyrosine kinases; and (5) tyrosine-kinase-associated receptors. The last two types of receptors are by far the most numerous, and they are thought to work in a similar way: ligand binding usually induces the receptors to dimerize, which activates the kinase activity of either the receptor or its associated nonreceptor tyrosine kinase. When activated, receptor tyrosine kinases usually cross-phosphorylate themselves on multiple tyrosine residues, which then serve as docking sites for a small set of intracellular signaling proteins. In this way, a multiprotein signalling complex is activated from which the signal spreads to the cell interior.
In addition to these numerous types of cell surface signalling receptors, cell signalling is also accomplished via intracellular cell signalling receptors. As indicated above, these receptors are inside the target cell and the signalling ligand has to enter the cell to activate them. Steroid hormones, thyroid hormones, retinoids, and vitamin D are examples of small hydrophobic molecules that differ greatly from one another in both chemical structure and function.
Nonetheless, they all act by a similar mechanism. They diffuse directly across the plasma membrane of target cells and bind to intracellular cell signalling receptors. Ligand binding activates the receptors, which then directly regulate the transcription of specific genes. These receptors are structurally related and constitute the intracellular receptor superfamily (or steroid-hormone receptor superfamily) .
Steroid hormone receptors include progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors. Thyroid hormone receptors include the thyroid stimulating hormone receptor.
Retinoid receptors include the receptor for retinoic acid.
According to the subject invention, a cell is transformed with DNA encoding one or more of these cell signalling receptors which is not endogenous to the cell (which may be a cell surface signalling receptor or an intracellular cell signalling receptor) . The non-endogenous receptor is capable of activating a signal transduction pathway that is endogenous to the cell. As used herein, a "non-endogenous" receptor is a receptor not normally present in/on (used interchangeably throughout this application) the particular cell. A receptor, therefore, may be non- endogenous to the transformed cell even though the receptor is present in/on other cells in the selected organism (i.e. in a human being) . For example, a receptor present only in heart muscle tissue is a "non- endogenous" receptor in a liver cell. In contrast, an "endogenous" pathway as used herein refers to a signal transduction pathway that is normally present in the transformed cell. Similarly, "ectopic" expression as used herein refers to expression of a receptor in/on a particular cell in/on which the receptor is not normally present. "Eutopic" expression, in contrast, is expression of a receptor in/on a particular cell in/on which the receptor is normally present.
The DNA encoding the non-endogenous receptor is capable of activating an endogenous signal transduction pathway in the transformed cell. Signal
transduction pathways are numerous, and include, for example, adenylate cyclase pathways, guanylate cyclase pathways, phosphoinositol turnover pathways, tyrosine kinase pathways, ion channel pathways, and calcium ion pathways. The initial signal produced by the binding of an extracellular signalling molecule to a cell signalling receptor is transduced intracellularly via a signal transduction pathway that may be multiple and interactive. Signal transduction pathways involve cAMP, cGMP, arachidonic acid, inositol 1,4, 5-tris-phosphate (IP3) , Ca2+, and other ions as second messengers and are produced by enzymes (such as adenylate and guanylate cyclases and phospholipases A2 and C) and ion channels. In many cases, an extracellular molecule-receptor complex does not interface directly with these effectors but acts via an intermediate modulating signal transducer, often a G protein. cAMP is the prototypical second messenger. Intracellular levels of cAMP are determined, in large part, by ligand-receptor interactions. This physiological event involves the interaction of three cellular components located near the plasma membrane: the ligand receptor, a signal transducer (G protein) , and the effector enzyme (adenylate cyclase) .
Cyclic AMP is a second messenger for many hormones, including epinephrine, glucagon, norepinephrine, parathyroid and luteinizing hormones, and thyroid-stimulating and melanocyte-stimulating hormones. Cyclic AMP affects a wide range of cellular processes: increases lipolysis, glycogen degradation, gluconeogenesis, ketogenesis, ion permeability of epithelia, renin production by kidney, contraction of cardiac muscle, HCl secretion by the gastric mucosa,
amylase release by the parotid gland, dispersion of melanin granules, and insulin release by the pancreas; decreases aggregation of platelets, and growth of tumor cells in tissue culture. The activation of adenyl cyclase leads to an increased amount of cyclic AMP inside the cell. Cyclic AMP then activates a protein kinase, which phosphorylates one or more proteins. For example, the phosphorylation of glycogen synthetase and phosphorylase kinase in muscle and liver results in decreased synthesis and enhanced degradation of glycogen. Table 1 classifies various hormone receptors and effectors according to the pathway utilized. Several receptors contain an intrinsic hormone-ac ivated tyrosine kinase activity.
Guanylate cyclase catalyzes the formation of cGMP from GTP, in analogy with adenylate cyclase. Guanylate cyclase, however, exists in cells in both soluble and membrane-associated forms. The membrane- associated form is regulated by hormones and other ligands. Like the tyrosine kinases and unlike adenylate cyclase, guanylate cyclase may directly serve receptor and effector functions.
A number of hormones and ligands mediate their cellular actions via calcium ions and DAG as second messengers. The second messengers, in turn, modulate the activity of protein kinases regulated by calcium binding-regulatory protein (e.g. calmodulin) , and DAG activates protein kinase C. These enzymes phosphorylate specific intracellular proteins, which results in further hormone action. Example of hormones using this signaling system in specific tissues include alpha-1-adrenergic and muscarinic cholinergic agents, vasopressin, histamine, cholecystokinin, LHRH,
thyrotropin-releasing hormone, angiotensin II, and oxytocin.
In general, the various hormone ligands that stimulate phosphoinositide turnover interact with the receptors that activate G proteins, as described for adenylate cyclase. These activated G proteins, however, are coupled to stimulation of phospholipase C activity.
Depending upon the pathway utilized, many different cellular functions are controlled by these various pathways. Numerous hormone-induced cellular responses are mediated by cyclic AMP, including: in the thyroid gland, thyroid-stimulating hormone (TSH) induces thyroid hormone synthesis and secretion; in the adrenal cortex, adrenocorticotropic hormone (ACTH) induces cortisol secretion; in the ovary, luteinizing hormone (LH) induces progesterone secretion; in muscle, adrenaline induces glycogen breakdown; in bone, parathormone induces bone resorption; in the heart, adrenaline induces an increase in heart rate and force of contraction; in the liver, glucagon induces glycogen breakdown; in the kidney, vasopressin induces water resorption; and in fat, adrenaline, ACTH, glucagon, and TSH induce triglyceride breakdown.
TABLE 1 Classification of Hormone Receptors and Kffectors
Adenylate cyclase
Beta-adrenergic catecholamines
Luteinizing hormone and human chorionic gonadotropin Follicle-stimulating hormone Corticotropin
Prostaglandins Parathyroid hormone Alpha-adrenergic (inhibition) TSH
Somatostatin (inhibition) Glucagon
Guanylate Cyclase
Atrial peptide (AP, also called atrial natriuretic factor)
Receptor Protein Tyrosine Kinases
Insulin
Insulin-like growth factor (somatomedin-C)
Epidermal growth factor Colony-stimulating factor 1
Fibroblast growth factor Platelet-derived growth factor
Phosphoinositol Turnover and Calcium Flux Acetylcholine receptor (muscarinic)
Alpha-adrenergic catecholamines Angiotensin
Luteinizing hormone-releasing hormone Vasopressin Thyrotropin-releasing hormone
Ion Channels
Acetylcholine receptor (nicotinic) Glycine Gamma-aminobutyric acid Kainate
Sodium Calcium Potassium
Unknown Effector System
Growth hormone Prolactin
Erythropoietin Interleukins
Nerve growth factor T cell receptor
Numerous cellular responses are mediated by G-protein-linked receptors coupled to the inositol- phospholipid signalling pathway, including: in the liver, the signalling molecule vasopressin induces glycogen breakdown; in the pancreas, the signalling molecule acetylcholine induces amylase secretion; in smooth muscle, the signalling molecule acetylcholine induces contraction; in mast cells, an antigen functions as a signalling molecule to induce histamine secretion; and in blood platelets, the signalling molecule thrombin induces aggregation.
These various cellular functions can thus be controlled by transforming a cell with DNA encoding a non-endogenous cell signalling receptor which is capable of activating one or more of these endogenous signal transduction pathways.
For a general discussion of cell signalling, see references (37-42) .
In addition to selecting a non-endogenous receptor and an endogenous signal transduction pathway, a method for transforming cells must also be selected. Various methods are known in the art. One of the first methods was microinjection, in which DNA was injected directly into the nucleus of cells through fine glass needles. This was an efficient process on a per cell basis, that is, a large fraction of the injected cells actually got the DNA, but only a few hundred cells could be injected in a single experiment.
The earliest method for introducing DNA into cells en masse was to incubate the DNA with an inert carbohydrate polymer (dextran) to which a positively charged chemical group (DEAE, for diethylaminoethyl) had been coupled. The DNA sticks to the DEAE-dextran via its negatively charged phosphate groups. These
large DNA-containing particles stick in turn to the surfaces of cells, which are thought to take them in by a process known as endocytosis. Some of the DNA evades destruction in the cytoplasm of the cell and escapes to the nucleus, where it can be transcribed into RNA like any other gene in the cell.
The DEAE-dextran method, while relatively simple, was very inefficient for many types of cells, so it was not a reliable method for the routine assay of the biological activity of a purified DNA preparation. The breakthrough that eventually made gene transfer a routine tool for workers studying mammalian cells was the discovery that cells efficiently took in DNA in the form of a precipitate with calcium phosphate. With this new method, the yield of virus from cells transfected with viral DNA was a hundred times greater than with the DEAE-dextran method.
Biological markers can be used to identify the cells carrying recombinant DNA molecules. In bacteria, these are commonly drug-resistance genes. Drug resistance is used to select bacteria that have taken up cloned DNA from the much larger population of bacteria that have not. In the early mammalian gene transfer experiments involving viral genes, the transfer of exogenous DNA into cells was detected because the DNA had a biological activity, it led to production of infectious virus or produced stable changes in the growth properties of the transfected cells. It was then discovered that the DNA tumor virus, herpes simplex virus (HSV) , contained a gene encoding the enzyme thymidine kinase (the tk gene) . The HSV tk gene can be used as a selectable genetic marker in mammalian cells in much the same way that
drug-resistance genes worked in bacteria, to allow rare transfected cells to grow up out of a much larger population that did not take up any DNA. The cells are transferred to selective growth medium, which permits growth only of cells that took up a functional tk gene (and the transferred DNA of interest) . Various dominant selectable markers are now known in the art, including: aminoglycoside phosphotransferase (APH) , using the drug G418 for selection which inhibits protein synthesis; the APH inactivates G418; dihydrofolate reductase (DHFR) :Mtx-resistant variant, using the drug methotrexate (Mtx) for selection which inhibits DHFR; the variant DHFR is resistant to Mtx; hygromycin-B-phosphotransferase (HPH) , using the drug hygromycin-B which inhibits protein synthesis; the HPH inactivates hygromycin B; thymidine kinase (TK) , using the drug aminopterin which inhibits de novo purine and thymidylate synthesis; the TK synthesizes thymidylate; xanthine-guanine phosphoribosyltransferase (XGPRT) , using the drug mycophenolic acid which inhibits de novo GMP synthesis; XGPRT synthesizes GMP from xanthine; and adenosine deaminase (ADA) , using the drug 9- /3-D-xylofuranosyl adenine (Xyl-A) which damages DNA; the ADA inactivates Xyl-A.
Gene amplification can also be used to obtain very high levels of expression of transfected gene.
When cell cultures are treated with Mtx, an inhibitor of a critical metabolic enzyme, DHFR, most cells die, but eventually some Mtx-resistant cells grow up. A gene to be expressed in cells is cotransfected with a
cloned dhfr gene, and the transfected cells are subjected to selection with a low concentration of Mtx. Resistant cells that have taken up the dhfr gene (and, in most cases, the cotransfected gene) multiply. Increasing the concentration of Mtx in the growth medium in small steps generates populations of cells that have progressively amplified the dhfr gene, together with linked DNA. Although this process takes several months, the resulting cell cultures capable of growing in the highest Mtx concentrations will have stably amplified the DNA encompassing the dhfr gene a hundredfold or more, leading to significant elevation of the expression of the cotransfected gene.
Although calcium phosphate coprecipitation is the most widely used method for introducing DNA into mammalian cells, in some cells it doesn't work. Cells such as lymphocytes, which grow in suspension, are especially resistant to transfection by calcium phosphate precipitates. In another method, electroporation, cells are placed in a solution containing DNA and subjected to a brief electrical pulse that causes holes to open transiently in their membranes. DNA enters through the holes directly into the cytoplasm, bypassing the endocytotic vesicles through which they pass in the
DEAE-dextran and calcium phosphate procedures (passage through these vesicles may sometimes destroy or damage DNA) . DNA can also be incorporated into artificial lipid vesicles, liposomes, which fuse with the cell membrane, delivering their contents directly into the cytoplasm. Microinjection, the surest way to get DNA into cells, can now be performed with a computer- assisted apparatus that increases by 10-fold or more the number of cells that can be injected in one
experiment. And in an even more direct approach, used primarily with plant cells and tissues, DNA is absorbed to the surface of tungsten microprojectiles and fired into cells with a device resembling a shotgun. Several of these methods, microinjection, electroporation, and liposome fusion, have been adapted to introduce proteins into cells. For review, see references (47-50) .
Although naked DNA introduced by transfection can be transiently expressed in up to half the cells in a culture, more frequently the fraction of transiently transfected cells is much lower. In fact, some cells are almost completely refractory to transfection by the artificial methods described above. Many applications of recombinant DNA technology require introducing foreign genes (i.e. non-endogenous receptors) into recalcitrant cell types. Potential gene therapy strategies, for example, require efficient means for transferring genes into normal human cells. To solve this problem, researchers have turned to viruses. Viral growth depends on the ability to get the viral genome into cells, and viruses have devised clever and efficient methods for doing it . The earliest viral vectors, based on the monkey tumor virus SV40, simply substituted some of the viral genes with the foreign gene. These recombinant molecules, prepared as bacterial plasmids, were transfected into monkey cells together with a second plasmid that supplied the missing viral genes. Once inside the cells, viral gene products produced from the two plasmids cooperate to replicate both plasmids and package each into virus particles. The virus stock that emerges from the cell is a mixture of two viruses, each of which is by itself defective (that is, it
cannot replicate on its own because it is missing necessary viral genes) . Nevertheless, this virus stock can then be used to infect new cells, efficiently introducing and expressing the foreign gene in the recipient cells.
A hybrid method that uses transfection to get DNA into cells and a viral protein to replicate it once inside is now commonly used for high-level production of protein from a cloned gene. This procedure uses a cell line, COS cells, carrying a stably integrated portion of the SV40 genome. These cells produce the viral T antigen protein, which triggers replication of viral DNA by binding to a DNA sequence termed the origin of replication. The foreign gene to be expressed is cloned into a plasmid that carries the SV40 origin of replication. After transfection into COS cells, the plasmid is replicated to a very high number of copies, increasing the expression level of the foreign gene. Use of SV-40-based viral vectors is limited for a number of reasons: they infect only monkey cells, the size of foreign gene that can be inserted is small, and the genomes are often rearranged or deleted. Other viral vectors are more commonly used now, either because they can infect a wider range of cells or because they accept a wider range of foreign genes. Vaccinia virus is a large DNA-containing virus that replicates entirely in the cytoplasm. Early vaccinia vectors incorporated the foreign gene directly into a nonessential region of the viral genome. Recombinant viruses are viable and upon infection transcribe the foreign gene from a nearby viral promoter. Because the viral genome is large (185,000 bp) , foreign genes cannot be inserted into vaccinia by standard
recombinant DNA methods; instead, it must be done by recombination inside cells, a cumbersome and lengthy procedure. A more versatile vaccinia expression system uses a ready-made recombinant virus that expresses a bacteriophage RNA polymerase. The gene to be expressed is simply cloned into a plasmid carrying a bacteriophage promoter. The plasmid is transfected into cells that have been previously infected with the vaccinia virus that expresses the RNA polymerase. The gene on the plasmid is efficiently transcribed by the bacteriophage polymerase, accounting for up to 30 percent of the RNA in the cell. An additional feature of vaccinia virus infection is that the virus shuts down host cell protein synthesis so that viral mRNA (and mRNA from the plasmid) are preferentially translated into protein.
Another virus widely used for protein production is an insect virus, baculovirus. Baculovirus attracted the attention of researchers because during infection, it produces one of its structural proteins (the coat protein) to spectacular levels. If a foreign gene were to be substituted for this viral gene, it too ought to be produced at high levels. Baculovirus, like vaccinia, is very large, and therefore foreign genes must be placed in the viral genome by recombination. To express a foreign gene in baculovirus, the gene of interest is cloned in place of the viral coat protein gene in a plasmid carrying a small portion of the viral genome. The recombinant plasmid is cotransfected into insect cells with wild¬ type baculovirus DNA. At a low frequency, the plasmid and viral DNAs recombine through homologous sequences, resulting in the insertion of the foreign gene into the viral genome. Virus plaques develop, and the plaques
containing recombinant virus look different because they lack the coat protein. The plaques with recombinant virus are picked and expanded. This virus stock is then used to infect a fresh culture of insect cells, resulting in high expression of the foreign protein. For a review of baculovirus vectors, see reference (51) .
All of the viruses discussed above are lytic viruses, in that they enter cells, take over, replicate massively, and get out, killing the cell in the process. So these vectors cannot be used to introduce a gene into cells in a stable fashion. This task is most ably performed by retroviruses. Retroviruses are RNA viruses with a life cycle quite different from that of the lytic viruses. When they infect cells, their RNA genomes are converted to a DNA form (by the viral enzyme reverse transcriptase) . The viral DNA is efficiently integrated into the host genome, where it permanently resides, replicating along with host DNA at each cell division. This integrated provirus steadily produces viral RNA from a strong promoter located at the end of the genome (in a sequence called the long terminal repeat or LTR) . This viral RNA serves both as mRNA for the production of viral proteins and as genomic RNA for new viruses. Viruses are assembled in the cytoplasm and bud from the cell membrane, usually with little effect on the cell's health. Thus, the retrovirus genome becomes a permanent part of the host cell genome, and any foreign gene placed in a retrovirus ought to be expressed in the cells indefinitely.
Retroviruses are therefore attractive vectors because they can permanently express a foreign gene in cells. Moreover, they can infect virtually every type
of mammalian cell, making them exceptionally versatile. Because of their versatility, retroviruses are also the vector of choice for gene therapy. In the design and use of retroviral vectors, the vectors usually contain a selectable marker as well as the foreign gene to be expressed. Most of the viral structural genes are gone, so these vectors cannot replicate as viruses on their own. To prepare virus stocks, cloned proviral DNA is transfected into a packaging cell. These cells usually contain an integrated provirus with all its genes intact, but lacking the sequence recognized by the packaging apparatus. Thus, the packaging provirus produces all the proteins required for packaging of viral RNA into infectious virus particles but it cannot package its own RNA. Instead, RNA transcribed from the transfected vector is packaged into infectious virus particles and released from the cell. The resulting virus stock is termed helper-free because it lacks wild-type replication-competent virus. This virus stock can be used to infect a target cell culture. The recombinant genome is efficiently introduced, reverse- transcribed into DNA (by reverse transcriptase deposited in the virus by the packaging cells) , and integrated into the genome. Thus, the cells now express the new virally introduced gene, but they never produce any virus, because the recombinant virus genome lacks the necessary viral genes. For a review of retrovirus vectors, see references (52,53) .
Another viral vector is adenovirus, reviewed by Berkner, K.L. (54) . Still another viral vector is herpesvirus.
As indicated, some of these methods of transforming a cell require the use of an intermediate plasmid vector. U.S. Patent No. 4,237,224 to Cohen and
Boyer describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture. The DNA sequences are cloned into the plasmid vector using standard cloning procedures in the art, as described by Maniatis et al . , Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1982) .
A transformed cell containing a foreign gene of interest (i.e., a non-endogenous receptor) can then be utilized for gene therapy purposes. Note that the cell may be transformed in vi tro and reinserted into a multicellular organism, or the cell may be transformed in vivo . In the same way that a retrovirus acts as a vector to carry a gene into a cell, so the cell can be regarded as a vector for carrying the gene into a patient's body.
Suitable cells for transformation and use in gene therapy should be readily obtainable, grow well in culture, and be able to withstand the various manipulations involved in, for example, retrovirus or adenovirus infection. For in vi tro transformation, vector cells should be easy to return to the patient after such transformation and should continue to live for many months, preferably for the life of the patient. See Friedmann (55) , Verma (56) , Anderson (62) and Mulligan (63) for discussions of gene therapy.
The cells of the bone marrow have many of these desirable features. The bone marrow contains stem cells that give rise to all cells of the hematopoietic series. Infection of these stem cells
results in a continuous supply of cells containing the therapeutic gene. Furthermore, the techniques for reconstituting the bone marrow of patients and experimental animals are well worked out . Convincing evidence that genes introduced in hematopoietic stem cells are expressed and that they can produce a therapeutic effect has come from experiments with a mutant dihydrofolate reductase gene (DHFR) . See Corey et al. (57) . Another cell type that has been studied intensively as a vehicle for gene transfer is the skin fibroblast. Fibroblasts are easily obtainable, grow well in culture, and have been the subjects of many experiments, and skin fibroblasts can be efficiently infected with viral vectors, such as retroviral vectors. See Palmer et al . (58) .
Another target tissue for gene therapy is the liver. A large number of inherited metabolic disorders affect the liver, and liver transplantation has been tried in an effort to treat these and other conditions such as hypercholesterolemia and hemophilia. Techniques have been developed for isolating and culturing hepatocytes, so the appropriate target cells are available for viral-mediated gene transfer. See Anderson et al . (59) .
One way to avoid the complications of developing cell-based systems for delivering genes to patients is to deliver the viral vectors directly to the target cells. This technique has been shown to be an efficient way to infect the endothelial cells of blood vessel walls using retroviral vectors. See Nabel et al . (60) and Nabel et al . (61) .
As indicated above, suitable cells to be transformed according to the subject invention include,
for example, a liver cell (known as a hepatocyte) in which one desires to control glycogenolysis. This can be accomplished by transforming the liver cell with DNA encoding a cell signalling receptor not endogenous to the cell (i.e. not normally present on the liver cell), where the receptor is capable of activating a signal transduction pathway endogenous (i.e. normally present in the cell) to the liver cell. The non-endogenous receptor is chosen such that the compatible signal transduction pathway regulates glycogenolysis in the cell. In the example of a liver cell, the cAMP pathway and phosphoinositide pathways within the liver cell regulate glycogenolysis, and DNA encoding a thyrotropin releasing hormone receptor (a receptor not endogenous to the liver cell) can be transformed into the liver cell to activate these two endogenous pathways, thereby providing for controllable activation of the pathways (by introducing an extracellular molecule capable of binding to the non-endogenous receptor and thereby stimulating the endogenous pathway) .
A liver cell is one example of a suitable in vivo cell according to the subject invention. Other cells are equally transformable, such as cells of the pulmonary airways. These cells can be transformed with a thyroid-stimulating hormone receptor which can utilize the pulmonary airways' endogenous cyclic AMP signal transduction pathway. Extracellular molecules capable of activating the thyroid-stimulating hormone receptor would therefore control the same cellular function as do adrenergic agonists and bronchodilating drugs (which utilize the cAMP pathway to normally control cellular function) .
The numerous other suitable cells would be apparent to those skilled in the art.
The particular examples which follow utilize adenovirus-based vectors to transform liver cells. Adenovirus based vectors have been used successfully to express a number of mammalian and viral proteins but they have not been used to ectopically express cell signalling receptors in vivo. The following examples show that functions of a specific cell type can be regulated in an intact animal by an agonist that does not usually affect functions in this cell type (because the cell does not endogenously express the receptor for this agonist) when the receptor for this agonist is expressed by adenovirus-mediated gene transfer. This is so because the expressed non-endogenous receptor couples to an endogenous signal transduction pathway and thereby regulates cell function.
As discussed below, receptors for the neurohormone thyrotropin-releasing hormone (TRH) were expressed by adenovirus-mediated gene transfer in the livers of intact rats. When administered to these rats but not to uninfected rats or to rats infected with a null virus, TRH caused an elevation of blood sugar. This rise in blood sugar is similar to that observed when vasopressin is given to rats because hepatocytes endogenously express receptors for vasopressin that signal through the same signal transduction system as the TRH receptor. In this manner, any receptor ectopically expressed in any cell type may be made to control functions of that cell.
This invention has important therapeutic applications. These applications include temporary relief of life-threatening illnesses, with receptor expression in diseased tissues and in tissues unaffected by the disease process. An example of an application in a diseased tissue would be the
expression of the receptor for thyroid-stimulating hormone in pulmonary airways to mediate, via an elevation of cyclic AMP, which is the same pathway used by adrenergic agonists and bronchodilating drugs, a bronchodilatory response in patients with chronic obstructive pulmonary disease or asthma suffering a marked exacerbation. A therapeutic advantage of using more than one receptor to mediate the desired response is that the efficacy of most drugs decreases upon repeated administrations, a process termed tachyphylaxis, which is usually caused by receptor desensitization. By activating different receptors at different times, one would anticipate a better therapeutic response. For example, in the patient suffering an episode of marked bronchoconstriction as described above, one would predict a better response to thyroid-stimulating hormone than to adrenergic agonists if adrenergic agonists had been used chronically.
Another application is for the treatment of diseases for which regulation of a physiologic function in a healthy organ would counter-balance the effects of a disease process. An example of this is presented in the Examples which follow, in which blood glucose was elevated by TRH after etopic expression of TRH receptors in liver. This approach can be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) to maintain normoglycemia over an extended period of time. In such a patient it might be better to ectopically express a non-endogenous receptor that signals via the cAMP transduction system, such as the receptor for thyroid-stimulating hormone, as glycogenolysis in human liver is more effectively regulated by this pathway than by the phosphoinositide pathway to which TRH
receptors couple. It is important to note that it would be better to use a non-peptide agonist drug rather than the natural peptide agonist so that receptor activation could be accomplished by an oral medication.
Maintenance of blood glucose by glycogenolysis in the liver is normally initiated by extracellular regulatory molecules such as glucagon and vasopressin triggering specific receptors on hepatocytes to activate the cAMP or phosphoinositide signal transduction pathways. The subject invention demonstrates that the normal ligand-receptor regulators of glycogenolysis can be bypassed using an adenovirus vector to ectopically express the non-endogenous mouse pituitary thyrotropin releasing hormone receptor
(TRH-R) cDNA in rat liver in vivo . The ectopically expressed TRH-R links to the phosphoinositide pathway, providing a means to activate glycogenolysis with TRH, an extracellular ligand not normally associated with liver physiology. When TRH is administered to these animals, the phosphoinositide path is activated resulting in a sustained rise in blood glucose. Since activation of a specific signal transduction pathway in a differentiated cell will trigger a cell-specific response independent of the ligands and receptors by which the signal transduction pathway is normally activated (8,9) , the invention provides an approach to the therapy of such disorders which is to bypass the normal extracellular regulatory molecule and its specific endogenous receptor by using an alternative ligand and non-endogenous receptor to trigger the relevant endogenous signal transduction pathway. Such a strategy can be used to correct abnormalities of extracellular regulatory molecules or
their specific endogenous receptors, as well as to modulate specific physiologic functions in disease states by re-establishing control of specific signal transduction pathways. The subject invention provides a new strategy to specifically control the differentiated function of cells in vivo by providing the means to trigger a specific signal transduction pathway by using a gene transfer vector to ectopically express a naturally occurring receptor in cells of an organ that do not normally express that receptor (i.e. a non-endogenous receptor) . The expressed receptor links to its natural signal transduction pathway, enabling specific responses to be triggered in the target cells by a ligand relevant for that receptor. For in vi tro data, see references (10-12) .
In the examples which follow, the consequences of systemic administration of thyrotropin- releasing hormone (TRH) after adenovirus-mediated transfer and ectopic expression of the thyrotropin- releasing hormone receptor (TRH-R) cDNA in hepatocytes in vivo is shown. The TRH-R is a seven transmembrane spanning receptor normally expressed in the anterior pituitary gland, and not in hepatocytes (13) . When TRH-Rs in pituitary cells are stimulated by TRH, the TRH-R triggers, via a guanine nucleotide binding protein, the phosphoinositide-calcium-protein kinase C signal transduction pathway and the pituitary releases thyroid stimulating hormone (TSH) (2,13,14) . In contrast, triggering of the phosphoinositide pathway in hepatocytes (for example, with vasopressin) results not in TSH release, but in glycogen breakdown and the release of glucose into the circulation (5) .
The subject invention provides for the transfer and expression of the TRH-R cDNA in hepatocytes in vivo with linkage of the expressed receptor to the hepatocyte phosphoinositide pathway. Therefore, systemic administration of TRH to animals expressing TRH receptors in the liver triggers the phosphoinositide pathway in hepatocytes, resulting in a rise in blood glucose.
Example I
Construction of AdCMV.mTRH-R:
The parent plasmid, pAdCMV.mTRH-R, was constructed by inserting a 1.2 kb EcoRI -NotI fragment containing the protein-coding region of the mouse TRH-R cDΝA, nucleotides 233-1462 of plasmid pBSmTRHR (43) , into plasmid pGEM2-L3-114 at the EcoRI-BamHI site. After digesting with EcoRI and using the Klenow fragment of DΝA polymerase I to make blunt DΝA ends, Hindlll linkers were ligated and a 1.4 kb Hindlll fragment containing mouse TRH-R cDΝA and the adenovirus E2 poly(A) signal sequence was isolated and inserted into the Hindlll site of the pAdCMV-HS-Vector which contains the left end replication and packaging elements of adenovirus, the cytomegalovirus-1 promoter and splicing elements from plasmid pML-IS Cat (44) . Following verification of the plasmid by restriction site mapping and transient transfection of pAdCMV.mTRH- R into COS-1 cells to demonstrate TRH-R expression, the virus AdCMV.mTRH-R was constructed by overlap recombination as described by Tantravahi et al . (45) . All transfections were carried out in human embryonic kidney cells transformed with the El region of adenovirus type 5 according to the procedure of Graham
et al . (46) . Following plaque purification, virus was grown in 293 cells in suspension cultures as described by Tantravahi et al . (45) . The entire sequence cdding for the adenovirus Ela gene was removed as well as the 5' 1.8 kb of the Elb gene. Co-transfection of pAdCMV.mTRH-R with the large fragment of adenovirus (3.8-100 map units) into 293 cells resulted in production of recombinant virus AdCMVmTRHR.
The construction of the recombinant plasmid designated pAdCMV.mTRH-R and the adenovirus vector designated AdCMV.mTHR-R is described fully by Gershengorn et al. (10) and Falck-Pedersen et al . (30) .
Example II
The ability of AdCMV.mTRH-R to transfer and express the mouse TRH-R cDNA in rat hepatocytes was first demonstrated in vi tro . The replication-deficient recombinant adenovirus vectors are all Ela", partial Elb", partial E3" based on adenovirus type 5, in which an expression cassette containing a promoter, driving the expression of a recombinant gene, is inserted at the site of the El deletion. AdCMV.mTRH-R contains an expression cassette with the cytomegalovirus early intermediate promoter/enhancer (CMV) followed by the mouse thyrotropin releasing hormone receptor (TRH-R) cDNA (30) . AdCMV.jSgal carries the CMV promoter and the E. coli LacZ gene [encoding /S-galactosidase (3gal)] (31) . The adenovirus vectors were prepared, purified, and titered as previously described (32,33) . Primary hepatocyte cultures established from 250-300 g male Sprague-Dawley rats (19) , were exposed to AdCMV.mTRH-R at different multiplicity of infection (moi, 1, 10, 50,
100) ; uninfected cells and cells infected with AdCMV./3gal (moi 50) were used as controls.
As shown in the Northern analysis of Fig. 1, RNA (10 μg/lane) from primary hepatocytes was evaluated 24 hr after incubation with the vectors using a mouse
TRH-R cDNA probe (lanes 1-6) , or as a positive control, human γ-actin cDNA probe (lanes 7-12) . The sizes of the transcripts are indicated. Incubation of the hepatocytes with AdCMV.mTRH-R resulted in a dose-dependent expression of TRH-R mRNA transcripts
(see Fig. 1, lanes 3-6) . In contrast, hepatocytes that were uninfected or infected with the control vector AdCMV.βgal demonstrated no TRH-R mRNA transcripts (see Fig. 1, lanes 1 and 2) , although control γ-actin mRNA transcripts were similar in all samples (see Fig. 1, lanes 7-12) .
Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone (methyl-TRH) to hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA. Preliminary studies demonstrated that methyl-TRH binding had a Kd of 3.18 ± 0.39 nM; based on this, 1 nM methyl-TRH was used for the binding studies. Following incubation for 24 hr with the vectors AdCMV.jβgal or AdCMV.mTRH-R, the hepatocytes (106/well) were incubated for 60 min with [3H] methyl-TRH (82.5 Ci/mmol, New England Nuclear-Dupont, Boston, MA) or [3H]methyl-TRH plus excess unlabeled methyl-TRH (Sigma, St. Louis, MO) . Free ligand was removed by aspirating the medium and washing the cells 5 times with 2 ml (4°C) Hanks balanced salt solution. Cell associated radioactivity was measured by dissolving the cells with 1 ml of 0.4 N NaOH and counting. Specific binding of the [3H] methyl- TRH was calculated as: [(dpm of [3H] methyl-TRH) - (dpM
[3H]methyl-TRH in the presence of unlabeled methyl-TRH)] (34) . For each dose of the vector, triplicate measurements were made in hepatocytes from two different animals. The number of TRH-R receptor sites was calculated assuming a one-to-one stoichiometry of ligand to receptor and a homogeneous distribution of TRH-Rs. Addition of labeled methyl-TRH [an analog with higher affinity than TRH (15) ] , demonstrated specific binding of methyl-TRH, with the amount of binding dependent on the dose of AdCMV.mTRH-R used to infect the hepatocytes (see Fig. 2) . In contrast, analysis of hepatocytes that were uninfected or infected with the control vector AdCMV./Sgal showed no specific binding of methyl-TRH (see Fig. 2) . Quantification of the number of binding sites of methyl-TRH demonstrated 5.7xl05 sites/cell with a Kd of 3.18 + 0.39 nM (AdCMV.mTRH-R 50 moi) . Following addition of methyl-TRH to the hepatocytes infected with AdCMV.mTRH-R, the ligand-receptor complex was internalized (not shown) . Fig. 3 shows the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA. Primary hepatocytes were exposed to the vectors AdCMV./3gal or AdCMV.mTRH-R. After 24 hr, the cells were labeled for 24 hr with myo- [3H] inositol (myo- [2-
3H] inositol; 20 Ci/mmol, Amersham Corporation, Arlington Heights, IL) , incubated (5 min, 37°C) with 10 mM LiCl, stimulated (60 min, 37°C) with methyl-TRH. The cells were then lysed, the inositol phosphates were separated by anion-exchange chromatography and the radioactivity counted. The fold stimulation of inositol phosphates formation was calculated as: (dpm in inositol phosphates x 100/dpm in lipids of stimulated cells) - (dpm in inositol phosphates x 100/dpm in lipids of
unstimulated cells) (35) . For each dose of vector, triplicate measurements were made in hepatocytes from two different animals.
Direct evidence of specific activation of the phosphoinositide pathway by TRH in AdCMV.mTRH-R infected hepatocytes was the demonstration of increased amounts of inositol phosphates in the hepatocytes infected with AdCMV.mTRH-R and stimulated with methyl-TRH (see Fig. 3) . Importantly, the increase in inositol phosphates was dependent on the dose of AdCMV.mTRH-R used to infect the cells, whereas hepatocytes that were uninfected, as well as hepatocytes infected with the control vector AdCMV./Sgal, showed no increase in inositol phosphates when incubated with methyl-TRH.
Example III
As observed in vi tro, the AdCMV.mTRH-R vector effectively transferred the TRH-R cDNA to the rat liver in vivo, with the consequent ectopic expression of functional TRH-Rs in the hepatocytes. To accomplish this, the AdCMV.mTRH-R was administered intravenously to the animals, a route of administration of replication deficient adenovirus vectors that results in > 90% detected expression of the exogenous gene in hepatocytes (16) .
Sprague-Dawley rats (250-300 g, 3 months old, fed ad libi tum) were anaesthetized with ketamine-HCl (60 mg/kg) and xylazine (5 mg/kg) . The Ad vectors [AdCMV.mTRH-R, AdCMV.jSgal, AdCMV.Null (the "Null" vector is similar to the other vectors except that the expression cassette contains the CMV promoter but no recombinant gene) (31)] were administered via the right
external jugular vein (5xl09 pfu, 100 μl 0.9% NaCl) . The livers were recovered 5 days later.
Cultures of primary hepatocytes from animals infected in vivo 5 days previously with AdCMV.mTRH-R demonstrated TRH-R mRNA transcripts, the ability to specifically bind TRH and the activation of the phosphoinositide pathway (Figs. 4-7) . Figs. 4 and 5 are Northern analyses. Liver RNA (10 μg/lane) was evaluated with a mouse TRH-R cDNA probe (Fig. 4, lanes 1 and 2) or, as a positive control, γ-actin cDNA (Fig. 5, lanes 3 and 4) . The sizes of the transcripts are indicated. Lanes 1 and 3 (Fig. 4 and Fig. 5, respectively) are animals receiving AdCMV./Sgal. Lanes 2 and 4 (Fig. 4 and Fig. 5, respectively) are animals receiving AdCMV.mTRH-R. Northern analysis of hepatocytes obtained from animals receiving the control vector AdCMV./Sgal demonstrated no TRH-R mRNA specific transcripts (Fig. 4, lane 1 and Fig. 5, lane 3) . In contrast, hepatocytes obtained from AdCMV.mTRH-R infected animals showed TRH-R mRNA transcripts of the expected size (see Fig. 4, lane 2) . As a control, γ-actin mRNA transcripts were observed in all samples. Consistent with this observation, hepatocytes recovered from animals receiving AdCMV.mTRH-R in vivo demonstrated high levels of methyl-TRH specific binding, whereas no specific methyl-TRH binding was observed in naive animals or animals receiving the control vector AdCMV./Sgal (Fig. 6) . The analysis of [3H]methyl-TRH binding was identical to that described for Fig. 2. Triplicate measurements were made from three individual animals per condition. The hepatocytes derived from the AdCMV.mTRH-R infected animals demonstrated 6. lxlO5 TRH-R receptors/cells, with a Kd of 2.51 ± 0.32 nM. The methyl-TRH complex
underwent internalization in hepatocytes from AdCMV.mTRH-R infected animals (not shown) .
Finally, addition of TRH to hepatocytes from uninfected animals and animals infected in vivo with the control vector AdCMV./Sgal showed no stimulation of inositol phosphate formation (Fig. 7) . Measurement of inositol phosphates formation was identical to that described for Fig. 3. Triplicate measurements were made from three individual animals per condition. In contrast, TRH activated the phosphoinositide pathway in hepatocytes from animals infected 5 days previously with the AdCMV.mTRH-R vector (16.9 ± 1.8 fold stimulation above the controls of no added methyl-TRH) . Evaluation of TRH stimulation as a function of time in these cultures demonstrated an increase in the formation of inositol phosphates over a period of at least 1 hr following addition of methyl-TRH (not shown) .
Example IV
The liver maintains blood glucose levels by secreting glucose derived from hepatocyte glycogen stores into the circulation. This process is regulated by specific cell-surface receptors activating either of two signal transduction pathways, the cAMP pathway or the phosphoinositide pathway. Both converge to activate phosphorylase B which cleaves glycogen to glucose-1-phosphate, which is then isomerized to glucose-6-phosphate by phosphoglucomutase, and finally dephosphorylated by glucose-6-phosphatase to glucose which is secreted (17) .
This example discloses the modulation in levels of serum glucose by TRH in animals following in
vivo transfer of the TRH-R cDNA to the liver. The vectors AdCMV.mTRH-R or AdCMV.Null (5xl09 pfu) , or saline (0.9%) as negative control (all in 100 μl) were administered to rats as described above. Five days later, the animals were anaesthetized by methoxyflurane (Pitman-Moore, Mundelein, IL) inhalation and the left and right external jugular veins were cannulated. After 15 min to permit stabilization, a 15 min baseline period was started, during which serum samples for glucose levels were obtained every 5 min. At "0 time" methyl-TRH (500 μg in 100 μl) or saline (0.9%, 100 μl) was administered in one cannula and the serum samples obtained from the other cannula every 5 min for 55 min. Serum glucose levels were determined by colormetric assay (Sigma Diagnostics, St. Louis, MO) .
Fig. 8 illustrates the modulation of serum glucose by TRH. The baseline glucose levels were determined for each animal as an average from -15 to 0 before administration of methyl-TRH or saline. The data are presented as the absolute change from the average baseline serum glucose level (mM) using each individual animal as its own control, and averaging the values at each time point for each group of animals. AdCMV.mTRH-R (IV) /TRH=vector administered intravenously at day 0, methyl-TRH administered at day 5, n=6 animals; AdCMV.mTRH-R(IP) /TRH= vector administered via the portal vein at day 0, methyl-TRH administered at day 5, n=5; AdCMV.Null (IV) /TRH=vector administered intravenously at day 0, methyl-TRH at day 5, n=6 ; saline/TRH=saline administered instead of vector at day 0, methyl-TRH at day 5, n=6; and naive/saline=nothing administered at day 0, saline at day 5, n=5. The data is presented as the mean for all animals in the group at each time point. The normal
range for serum glucose Sprague-Dawley rats is 2.5 - 6.7 mM(36) . The average baseline values (mean ± standard deviation) were: AdCMV.mTRH-R(IV) /TRH group 6.1 ± 0.8 mM; AdCMV.mTRH-R(IP) /TRH group 5.6 ± 0.5 mM; AdCMV.Null (IV) /TRH group 4.6 ± 0.5 mM;
AdCMV.Null (IV) /saline group 7.9 ± 1.8 mM; saline (IV) /TRH group 9.2 ± 1.4 mM; and naive/saline group 8.6 ± 0.7 mM.
Fig. 9 illustrates the average change in serum glucose levels from baseline. The average change in serum glucose levels from baseline was determined for each time point from 15 to 55 min after administration of methyl-TRH or saline on day 5. The data are presented as mean + standard deviation. All statistical comparisons were made using the two-tailed Student's t-test.
Initial studies demonstrated that a stable blood glucose level could be established by using inhalation anesthesia and limiting environmental stimuli during the experimental studies (18) . As a positive control, when [Arg8] vasopressin (1 μg in 100 μl 0.9% NaCl) was administered by the intravenous route, there was an increase in blood glucose, followed by a decrease over the 55 min period of evaluation (not shown) .
Consistent with the ability of TRH to activate the phosphoinositide pathway in hepatocytes isolated from animals receiving the AdCMV.mTRH-R vector 5 days previously, and the knowledge that activation of the phosphoinositide pathway in hepatocytes initiates glycogenolysis, intravenous administration of methyl-TRH induced a significant increase in blood glucose levels in a group of animals receiving AdCMV.mTRH-R 5 days previously (Fig. 8) . In the group
of animals receiving saline, and 5 days later, intravenous methyl-TRH, there was a small increase in blood glucose over the baseline levels, similar to that observed in the group administered AdCMV. ull followed 5 days later by intravenous methyl-TRH, and in the naive group administered saline. However, the increase in blood glucose over baseline levels observed in each of these control groups was minimal compared to the increase in blood glucose over baseline induced by methyl-TRH in animals receiving the AdCMV.mTRH-R vector by the intravenous route 5 days previously. In these animals, the rise in blood glucose peaked 15 min after the administration of methyl-TRH, and the elevation in blood glucose levels was maintained for at least 55 min, the time at which the experiment was terminated. The increase in blood glucose over baseline from 15 to 55 min after methyl-TRH administration was 1.73 ± 0.26 mM, an increase markedly higher than that observed in any of the controls over the same period (saline (IV) /TRH, naive/saline, AdCMV.Null (IV) /TRH and
AdCMV.Null (IV) /saline, p<0.0001 all comparisons) (Fig. 9) .
Direct support for the concept that the liver was responsible for the rise in blood glucose came from administration of the AdCMV.mTRH-R vector to rats via the portal vein [a route of administration of an adenovirus vector to rats known to result in limitation of vector gene expression only in hepatocytes (19,20)] , followed 5 days later by the administration of intravenous methyl-TRH. In these animals, the observed rise in blood glucose was superimposable upon that observed in animals receiving the AdCMV.mTRH-R vector intravenously followed 5 days later by administration of methyl-TRH (AdCMV.mTRH-R administered via portal
vein compared to AdCMV.mTRH-R administered intravenously averaged 15 to 55 min after methyl-TRH, p=0.09; portal vein administration of AdCMV.mTRH-R followed by methyl-TRH compared to control groups, p<0.0001 all comparisons) (Figs. 8 and 9) .
Example V
The present invention supports the concept that ectopic expression of a non-endogenous naturally occurring receptor can be used to control differentiated functions of cells in vivo, using the natural ligand for the receptor to activate the receptor, and in turn, activate a specific signal transduction pathway in the cell, thus triggering a cell-specific response. Put into the context of the availability of vectors that can transfer genes in vivo to most organs, the strategy can be used as an alternative means to modulate specific differentiated functions of cells using naturally occurring ligands or receptor-specific drugs and their corresponding receptors not normally relevant to that cell type. The strategy of expressing natural receptors as described herein adds to a growing list of strategies to modify receptor number and/or function, including overexpression of natural receptors in their natural location (21) and "designer" receptors that respond to artificial ligands (22) as means of triggering specific signal transduction pathways to activate specific differentiated functions of cells, and the transfer of normal receptors to their normal location to compensate for mutations in the natural receptor (23,24) .
Clinical applications of this strategy include activation of differentiated functions that are
impotent and/or dysfunctional secondary to inherited or acquired abnormalities associated with signalling molecules or their specific receptors. In addition to deficiencies in signalling secondary to mutations in genes coding for hormones or receptors (1,6,25,26) , such a strategy could be used to bypass acquired ligand deficiency states associated with antibodies directed against the ligand, such as observed in individuals with diabetes receiving insulin of human and non-human origin, polyclonal anti-insulin antibodies in individuals with various autoimmune disorders and anti- thyroxine antibodies in patients with immune thyroid disease and plasma cell dyscrasias (1,6,7) . In addition, there are a group of acquired disorders in which receptor-specific autoantibodies intercept the ability of extracellular regulatory molecules to interact with their specific receptors, including the autoantibodies against βl-adrenergic receptors implicated in the pathogenesis of idiopathic dilated cardiomyopathy and the cardiomyopathy associated with Chagas' disease, autoantibodies against β2 -adrenergic receptors linked to the pathogenesis of some forms of asthma, antibodies to the insulin receptor associated with the diabetes found and type B insulin resistance observed in individuals with acanthosis nigricans and ataxia telangiectasia, autoantibodies to the acetylcholine receptor in myasthenia gravis and to the glutamate receptor in Rasmussen's encephalitis (1,6,7,27,28) . Finally, this strategy may also be applied to the treatment of diseases for which regulation of a physiologic function in a healthy organ would counterbalance the effects of a disease process. An example of this is suggested by the previous examples, in which blood glucose was elevated by TRH
after ectopic expression of TRH-Rs in liver. This approach could be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) in order to maintain normoglycemia over an extended period of time (29) . Not only could this be achieved by triggering the phosphoinositide pathway (e.g., TRH and TRH-Rs expressed in liver) , but perhaps more effectively, by expressing in the liver a no -endogenous receptor that signals via the cAMP transduction system, since glycogenolysis in human liver is more effectively regulated by this pathway than by the phosphoinositide pathway, and for which oral non-peptide agonist drugs are available for activation. Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.
LIST OF REFERENCES CITED
1. S. Gammeltoft and R. C. Kahn, Endocrinology, L.J. DeGroot, et al . , Eds., W.B. i Saunders Company, Philadelphia (1995) , p. 17.
2. M. C. Gershengorn and J. H. Perlman, Endocrinology, L.J. DeGroot, et al., Eds., W.B. Saunders Company, Philadelphia (1995) , p. 66.
3. J. F. Habener, Endocrinology, L.J. DeGroot, et al . , Eds., W.B. Saunders Company, Phila¬ delphia (1995) , p. 77. 4. D. A. Walsh and S. M. Van Patten, FASEB J
8:1227 (1994) .
5. J. H. Exton, Diabetes Metab Rev 3:163 (1987) .
6. J. R. Raymond, Am J Physiol 266:F163 (1994) .
7. T. J. Wilkin, N Engl J Med 323:1318 (1990) .
8. Y. Tsunoda, Biochim Biophys Acta 1154:105 (1993) . 9. L. Birnbaumer, et al . , Crit Rev Biochem
Mol Biol 25:225 (1990) .
10. M. C. Gershengorn, et al . , J Biol Chem 269:6779 (1994) .
11. F. R. Bringhurst et al . , Endocrinology 132:2090 (1993) .
12. K. J. Kaneko, et al . , Biochemis try 32:8348 (1993) .
13. M. C. Gershengorn, Recent Prog Horm Res 48 :341 (1993) . 14. M. F. Scanlon and R. Hall,
Endocrinology, L.J. DeGroot, et al . , Eds., W.B.
Saunders Company, Philadelphia (1995) , p. 192.
15. W. Vale, et al . , Endocrinology 89:1485 (1971) .
16. J. Herz and R. D. Gerard, Proc Na tl Acad Sci 90:2812 (1993) .
17. S. J. Pilkis and D. K. Granner, Annu Rev Physiol 54:885 (1992) .
18. A. A. Young, et al . , Am J Physiol 264 :E943 (1993) . 19. H. A. Jaffe et al . , Na t Genet 1:372
(1992) .
20. Q. Li, et al . , Hum Gene Ther 4:403
(1993)
21. C. A. Milano, et al . , Sci ence 264:582 (1994)
22. D. M. Spencer, et al . , Science 262:1019 (1993)
23. M. Grossman, et al . , Na t Genet 6:335 (1994) 24. K. F. Kozarsky, et al . , J Biol Chem
269:13695 (1994) .
25. R. J. Lefkowitz and R. T. Premont, J Clin Inves t 92:2089 (1993) .
26. A. M. Spiegel, et al . , J" Clin Invest 92:1119 (1993) .
27. S. W. Rogers, et al . , Science 265:648 (1994) .
28. Y. Naparstek and P. H. Plotz, Annu Rev Immunol 11:79 (1993) . 29. J. A. Norton, Curr Probl Surg 31:77
(1994) .
30. E. Falck-Pedersen, et al . , Mol Pharmacol 45:684 (1994) .
31. J. Hersh, et al . , Gene Therapy 2:124 (1995) .
32. M. A. Rosenfeld, et al . , Sci ence 252:431 (1991) .
33. M. A. Rosenfeld, et al . , Cell 68:143 (1992) .
34. M. C. Gershengorn, J Clin Invest 62:937 (1978) .
35. A. Imai and M. C. Gershengorn, Methods Enzymol 141:100 (1987) . 36. B. M. Mitruka and H. M. Rawnsley,
Clini cal Biochemi cal and Hema tologi cal Reference Val ues in Normal Experimental Animals , Masson, New York (1977) , p. 117. 37. Barritt, G.J. Communica tion Wi thin
Animal Cells . Oxford, UK: Oxford Science Publications, 1992.
38. Hardie, D.G. Biochemical Messengers : Hormones, Neurotransmi t ters and Growth Factors . London: Chapman and Hall. 1990.
39. Molecular Biology of Signal Transduction . Cold Spring Harbor Symposium Quant. Biol., Vol. 53. 1988.
40. Morgan, Ν.G. Cell Signalling. Milton Kaynes, UK: Open University Press, 1989. 41. Kahn, C.R., J Cell Biol 70:261-286
(1976) .
42. Snyder, S.H., Sci Am 253 (4) : 132-140 (1985) .
43. Straub et al . , Proc Na tl Acad Sci USA, 87:9514-9518 (1990) .
44. Huang et al . , Nucleic Acids Res, 18:937- 947 (1990) .
45. Tantravahi et al . , Mol Cell Biol 13:578- 587 (1993) . 46. Graham et al . , J Gen Virol 36:59-72
(1977) .
47. Mannino, R.J. and S. Gould-Fogerite, BioTechniques 6:682-690 (1988) .
48. Shigekawa, K. and W.J. Dower, BioTechniques 6:742-751 (1988) .
49. Capecchi, M., Cell 22:479-488 (1980) .
50. Klein, T.M., et al . , Na ture 327:70-73 (1987) .
51. Miller, L.K., Bioessays 11:91-95 (1989) 52. Cepko, C, Neuron 1:345-353 (1988) .
53. Eglitis, M.A. and W.F. Anderson,
BioTechniques 6:608-614 (1988) . 54. Berkner, K.L., BioTechniques 6:616-629
(1988) .
55. Friedmann, T., Science 244:1275-1281
(1989)
56. Verma, I.M., Sci Am 262 : 68-84 (1990) .
57. Corey, C.A., et al . , Blood 75:337-343
(1990) .
58. Palmer, T.D., et al . , Proc Na tl Acad Sci USA 84:1055-1059 (1987) .
59. Anderson, K.D., et al . , Soma t Cell Mol Genet 15:215-217 (1989) .
60. Νabel, E.G., et al . , Science 244:1342- 1344 (1989) . 61. Νabel, E.G., et al . , Science 249:1285-
1288 (1990) .
62. Anderson, W.F., Sci ence 256:808-813
(1992) .
63. Mulligan, R.C, Science 260:926-932
(1993) .
Claims
1. A recombinant in vivo cell comprising: an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to said cell, said cell signalling receptor capable of activating a signal transduction pathway endogenous to said cell, wherein said cell signalling receptor can be controllably activated thereby controllably activating said signal transduction pathway so as to regulate a cell function controlled by said signal transduction pathway.
2. The recombinant in vivo cell of claim 1 wherein said cell is a cell of an organ.
3. The recombinant in vivo cell of claim 2 wherein said organ is liver and said cell is a hepatocyte.
4. The recombinant in vivo cell of claim 1 wherein said receptor is a cell surface signalling receptor.
5. The recombinant in vivo cell of claim 4 wherein said cell surface signalling receptor is an ion-channel linked receptor.
6. The recombinant in vivo cell of claim 5 wherein said ion-channel linked receptor is selected from the group consisting of a sodium channel linked receptor, a potassium channel linked receptor, a calcium channel linked receptor, and a chloride channel linked receptor.
7. The recombinant in vivo cell of claim 4 wherein said cell surface signalling receptor is a guanine-nucleotide binding protein linked receptor.
8. The recombinant in vivo cell of claim 7 wherein said guanine-nucleotide binding protein linked receptor is selected from the group consisting of alpha-adrenergic receptors, beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, and peptidergic receptors .
9. The recombinant in vivo cell of claim 7 wherein said guanine-nucleotide binding protein linked receptor is a thyrotropin releasing hormone receptor.
10. The recombinant in vivo cell of claim 4 wherein said cell surface signalling receptor is an enzyme linked receptor.
11. The recombinant in vivo cell of claim 10 wherein said enzyme linked receptor is selected from the group consisting of transmembrane guanylyl cyclase receptors, receptor tyrosine phosphatases, transmembrane receptor serine/threonine kinases, receptor tyrosine kinases, and tyrosine-kinase- associated receptors.
12. The recombinant in vivo cell of claim 1 wherein said receptor is an intracellular cell signalling receptor.
13. The recombinant in vivo cell of claim 12 wherein said intracellular cell signalling receptor is a steroid hormone receptor.
14. The recombinant in vivo cell of claim 13 wherein said steroid hormone receptor is selected from the group consisting of progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors.
15. The recombinant in vivo cell of claim 12 wherein said intracellular cell signalling receptor is a thyroid hormone receptor.
16. The recombinant in vivo cell of claim 15 wherein said thyroid hormone receptor comprises a receptor for thyroid stimulating hormone.
17. The recombinant in vivo cell of claim 12 wherein said intracellular cell signalling receptor is a retinoid receptor.
18. The recombinant in vivo cell of claim 17 wherein said retinoid receptor comprises a receptor for retinoic acid.
19. The recombinant in vivo cell of claim 12 wherein said intracellular cell signalling receptor is a vitamin D receptor.
20. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is an adenylate cyclase pathway.
21. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is a guanylate cyclase pathway.
22. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is a phosphoinositol turnover pathway.
23. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is a tyrosine kinase pathway.
24. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is an ion channel pathway.
25. The recombinant in vivo cell of claim 1 wherein said signal transduction pathway is a calcium ion pathway.
26. The recombinant in vivo cell of claim 1 wherein said cell function is glycogenolysis.
27. The recombinant in vivo cell of claim 1 wherein said cell function is selected from the group consisting of: lipolysis, gluconeogenesis, ketogenesis, ion permeability, renin production, muscle contraction, protein phosphorylation, thyroid hormone synthesis, cortisol secretion, progesterone secretion, bone resorption, water resorption, triglyceride breakdown, amylase secretion, histamine secretion, and aggregation.
28. A method of ectopically expressing a non-endogenous receptor in a cell, said method comprising: selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to said cell, said cell signalling receptor capable of activating a signal transduction pathway endogenous to said cell; transforming said cell with DNA encoding said cell signalling receptor; and ectopically expressing said cell signalling receptor in said cell.
29. The method of claim 28 wherein said transformation comprises viral mediated transformation.
30. The method of claim 29 wherein said viral mediated transformation comprises adenovirus mediated transformation.
31. The method of claim 29 wherein said viral mediated transformation comprises herpesvirus mediated transformation.
32. The method of claim 28 wherein said transformation comprises liposome mediated transformation.
33. The method of claim 28 wherein said transformation comprises chemically mediated transformation.
34. The method of claim 33 wherein said chemically mediated transformation comprises calcium phosphate mediated transformation.
35. The method of claim 28 wherein said cell is a cell of an organ.
36. The method of claim 35 wherein said organ is liver and said cell is a hepatocyte.
37. The method of claim 28 wherein said receptor is a cell surface signalling receptor.
38. The method of claim 37 wherein said cell surface signalling receptor is an ion-channel linked receptor.
39. The method of claim 38 wherein said ion- channel linked receptor is selected from the group consisting of a sodium channel linked receptor, a potassium channel linked receptor, a calcium channel linked receptor, and a chloride channel linked receptor.
40. The method of claim 37 wherein said cell surface signalling receptor is a guanine-nucleotide binding protein linked receptor.
41. The method of claim 40 wherein said guanine-nucleotide binding protein linked receptor is selected from the group consisting of alpha-adrenergic receptors, beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, and peptidergic receptors.
42. The method of claim 40 wherein said guanine-nucleotide binding protein linked receptor is a thyrotropin releasing hormone receptor.
43. The method of claim 37 wherein said cell surface signalling receptor is an enzyme linked receptor.
44. The method of claim 43 wherein said enzyme linked receptor is selected from the group consisting of transmembrane quanylyl cyclase receptors, receptor tyrosine phosphatases, transmembrane receptor serine/threonine kinases, receptor tyrosine kinases, and tyrosine-kinase-associated receptors.
45. The method of claim 28 wherein said receptor is an intracellular cell signalling receptor.
46. The method of claim 45 wherein said intracellular cell signalling receptor is a steroid hormone receptor.
47. The method of claim 46 wherein said steroid hormone receptor is selected from the group consisting of progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors.
48. The method of claim 45 wherein said intracellular cell signalling receptor is a thyroid hormone receptor.
49. The method of claim 48 wherein said thyroid hormone receptor comprises a receptor for thyroid stimulating hormone.
50. The method of claim 45 wherein said intracellular cell signalling receptor is a retinoid receptor.
51. The method of claim 50 wherein said retinoid receptor comprises a receptor for retinoic acid.
52. The method of claim 45 wherein said intracellular cell signalling receptor is a vitamin D receptor.
53. The method of claim 28 wherein said signal transduction pathway is an adenylate cyclase pathway.
54. The method of claim 28 wherein said signal transduction pathway is a guanylate cyclase pathway.
55. The method of claim 28 wherein said signal transduction pathway is a phosphoinositol turnover pathway.
56. The method of claim 28 wherein said signal transduction pathway is a tyrosine kinase pathway.
57. The method of claim 28 wherein said signal transduction pathway is an ion channel pathway.
58. The method of claim 28 wherein said signal transduction pathway is a calcium ion pathway.
59. The method of claim 28 wherein said cell function is glycogenolysis.
60. The method of claim 28 wherein said cell function is selected from the group consisting of : lipolysis, gluconeogenesis, ketogenesis, ion permeability, renin production, muscle contraction, protein phosphorylation, thyroid hormone synthesis, cortisol secretion, progesterone secretion, bone resorption, water resorption, triglyceride breakdown, amylase secretion, histamine secretion, and aggregation.
61. A method of regulating a cell function, said method comprising: selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to said cell, said cell signalling receptor capable of activating a signal transduction pathway endogenous to said cell; transforming said cell with DNA encoding said cell signalling receptor; ectopically expressing said cell signalling receptor in said cell; and controllably exposing said cell to an extracellular molecule capable of activating said cell signalling receptor, wherein activation of said cell signalling receptor activates said signal transduction pathway so as to regulate a cell function controlled by said signal transduction pathway.
62. The method of claim 61 wherein said transformation comprises viral mediated transformation.
63. The method of claim 62 wherein said viral mediated transformation comprises adenovirus mediated transformation.
64. The method of claim 62 wherein said viral mediated transformation comprises herpesvirus mediated transformation.
65. The method of claim 61 wherein said transformation comprises liposome mediated transformation.
66. The method of claim 61 wherein said transformation comprises chemically mediated transformation.
67. The method of claim 66 wherein said chemically mediated transformation comprises calcium phosphate mediated transformation.
68. The method of claim 61 wherein said cell is a cell of an organ.
69. The method of claim 68 wherein said organ is liver and said cell is a hepatocyte.
70. The method of claim 61 wherein said receptor is a cell surface signalling receptor.
71. The method of claim 70 wherein said cell surface signalling receptor is an ion-channel linked receptor.
72. The method of claim 71 wherein said ion- channel linked receptor is selected from the group consisting of a sodium channel linked receptor, a potassium channel linked receptor, a calcium channel linked receptor, and a chloride channel linked receptor.
73. The method of claim 70 wherein said cell surface signalling receptor is a guanine-nucleotide binding protein linked receptor.
74. The method of claim 73 wherein said guanine-nucleotide binding protein linked receptor is selected from the group consisting of alpha-adrenergic receptors, beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, and peptidergic receptors.
75. The method of claim 73 wherein said guanine-nucleotide binding protein linked receptor is a thyrotropin releasing hormone receptor.
76. The method of claim 70 wherein said cell surface signalling receptor is an enzyme linked receptor.
77. The method of claim 76 wherein said enzyme linked receptor is selected from the group consisting of transmembrane quanylyl cyclase receptors, receptor tyrosine phosphatases, transmembrane receptor serine/threonine kinases, receptor tyrosine kinases, and tyrosine-kinase-associated receptors.
78. The method of claim 61 wherein said receptor is an intracellular cell signalling receptor.
79. The method of claim 78 wherein said intracellular cell signalling receptor is a steroid hormone receptor.
80. The method of claim 79 wherein said steroid hormone receptor is selected from the group consisting of progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors.
81. The method of claim 78 wherein said intracellular cell signalling receptor is a thyroid hormone receptor.
82. The method of claim 81 wherein said thyroid hormone receptor comprises a receptor for thyroid stimulating hormone.
83. The method of claim 78 wherein said intracellular cell signalling receptor is a retinoid receptor.
84. The method of claim 83 wherein said retinoid receptor comprises a receptor for retinoic acid.
85. The method of claim 78 wherein said intracellular cell signalling receptor is a vitamin D receptor.
86. The method of claim 61 wherein said signal transduction pathway is an adenylate cyclase pathway.
87. The method of claim 61 wherein said signal transduction pathway is a guanylate cyclase pathway.
88. The method of claim 61 wherein said signal transduction pathway is a phosphoinositol turnover pathway.
89. The method of claim 61 wherein said signal transduction pathway is a tyrosine kinase pathway.
90. The method of claim 61 wherein said signal transduction pathway is an ion channel pathway.
91. The method of claim 61 wherein said signal transduction pathway is a calcium ion pathway.
92. The method of claim 61 wherein said cell function is glycogenolysis.
93. The method of claim 61 wherein said cell function is selected from the group consisting of: lipolysis, gluconeogenesis, ketogenesis, ion permeability, renin production, muscle contraction, protein phosphorylation, thyroid hormone synthesis, cortisol secretion, progesterone secretion, bone resorption, water resorption, triglyceride breakdown, amylase secretion, histamine secretion, and aggregation.
94. The method of claim 61 wherein said extracellular molecule comprises a drug.
95. The method of claim 61 wherein said cell function is malfunctioning in said cell prior to said exposure of said cell to said extracellular molecule.
96. The method of claim 61 wherein said malfunction is due to desensitization of an endogenous receptor normally present on said cell and normally capable of activating said signal transduction pathway.
97. The method of claim 61 wherein said malfunction is due to absence or mutation of an endogenous receptor normally present on said cell and normally capable of activating said signal transduction pathway.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67721/96A AU716407B2 (en) | 1995-08-14 | 1996-08-12 | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors |
EP96928135A EP0845045A4 (en) | 1995-08-14 | 1996-08-12 | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors |
JP9509404A JPH11510704A (en) | 1995-08-14 | 1996-08-12 | Regulation of cell function by ectopic expression of non-endogenous cell signal receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US225495P | 1995-08-14 | 1995-08-14 | |
US60/002,254 | 1995-08-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09011624 A-371-Of-International | 1998-06-04 | ||
US10/291,007 Continuation US20030073662A1 (en) | 1995-08-14 | 2002-11-08 | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997007233A1 WO1997007233A1 (en) | 1997-02-27 |
WO1997007233A9 true WO1997007233A9 (en) | 1997-05-09 |
Family
ID=21699924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/013077 WO1997007233A1 (en) | 1995-08-14 | 1996-08-12 | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0845045A4 (en) |
JP (1) | JPH11510704A (en) |
AU (1) | AU716407B2 (en) |
CA (1) | CA2229287A1 (en) |
WO (1) | WO1997007233A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
DE68927996T2 (en) * | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | MODIFIED HEPATOCYTES AND THEIR USE |
US5462856A (en) * | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
US5401629A (en) * | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
AU5457294A (en) * | 1992-10-29 | 1994-05-24 | Board Of Regents, The University Of Texas System | Adenovirus-mediated ldl receptor gene transfer and targeting |
DK0698109T3 (en) * | 1993-05-10 | 2002-11-25 | Univ Michigan | Gene transfer to pancreatic epithelial cells |
GB9311854D0 (en) * | 1993-06-09 | 1993-07-28 | Medical Res Council | Trh receptor action |
WO1995016772A1 (en) * | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
-
1996
- 1996-08-12 CA CA002229287A patent/CA2229287A1/en not_active Abandoned
- 1996-08-12 AU AU67721/96A patent/AU716407B2/en not_active Ceased
- 1996-08-12 JP JP9509404A patent/JPH11510704A/en active Pending
- 1996-08-12 WO PCT/US1996/013077 patent/WO1997007233A1/en not_active Application Discontinuation
- 1996-08-12 EP EP96928135A patent/EP0845045A4/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2279441C2 (en) | Isolated soluble il-20 receptor (variants) | |
Fletcher et al. | Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity | |
US5854067A (en) | Hexokinase inhibitors | |
Ruth | Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting | |
DE60034450T2 (en) | 22025, A NEW HUMAN CYCLIC NUCLEOTIDE PHOSPHODIESTERASE | |
US5891717A (en) | Methods and compositions for inhibiting hexokinase | |
US6353152B1 (en) | Corticotropin releasing factor receptor 2 deficient mice and uses thereof | |
KR20160032090A (en) | Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function | |
CN109071678A (en) | Nerve growth factor fusion protein, preparation method and its usage | |
US6511811B1 (en) | Protein kinase C antagonist related to insulin receptor | |
US7083793B2 (en) | Tango 243 polypeptides and uses thereof | |
AU716407B2 (en) | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors | |
US6518480B1 (en) | Selective target cell activation by expression of a G protein-coupled receptor activated superiorly by synthetic ligand | |
US20030073662A1 (en) | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors | |
WO1997007233A9 (en) | Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors | |
AU7869994A (en) | Methods of suppressing autoimmune response | |
Wolff et al. | Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH | |
US7432361B2 (en) | G protein-coupled receptor, GAVE10 | |
KR20230145148A (en) | Gene Therapy for Retinal Diseases | |
Monnier et al. | CRH AND PACAP REGULATE EARLY IMMEDIATE AND NEUROPEPTIDE GENES IN PITUITARY CELLS AND NEURONS. | |
US20030059869A1 (en) | Novel G protein-coupled receptor, GAVE3 | |
US20030211577A1 (en) | Novel G protein-coupled receptor, GAVE7 | |
US20030236194A1 (en) | Novel G protein-coupled receptor, GAVE2 | |
US20030064434A1 (en) | Novel G Protein-coupled receptor, GAVE1 | |
Guthrie | Neural-specific isoforms of protein kinase A and the role of protein kinases in neural gene expression |